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Abstract
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme that catalyses the Smethylation of aromatic and sulphydryl compounds known as the thiopurines. These
therapeutic agents are used in the treatment of acute lymphoblastic leukemia,
autoimmune disorders, inflammatory bowel disease and organ transplant recipients.
Erythrocyte TPMT activity is polymorphic and patients with intermediate or deficient
TPMT are at significant risk for excessive toxicity after receiving ‘standard’ doses of
thiopurine medications. The activity of TPMT is inherited as an autosomal co-dominant
trait. Several mutations in the TPMT gene have been described that correlate with a low
activity phenotype. Three mutations G238C, G460A and A719G account for the
majority (96%) of the genetic polymorphisms found in all human populations studied to
date. Significant ethnic differences in the frequency of these mutant alleles have been
reported.

Advances in DNA analysis have led to the development of molecular approaches to aid
in the predictive diagnosis of TPMT deficiency and determine heterozygosity, a step
that has immense benefit for the prognostic outcome. Using such assays a sample
population (100) was assessed for the presence of the three most common TPMT
mutations.

In this work, the design of allele specific oligonucleotides for G460A and A719G
permitted the development of Amplification Refractory Mutation Detection System
(ARMS) assays for these mutations.

A novel multiplex ARMS PCR assay was designed to simultaneously detect the three
most prevalent mutations using two formats i.e. conventional agarose gel
electrophoresis and GeneScan analysis. The results of these new assays were compared
with those conventional molecular approaches and the results were found to be in exact
correlation. Of the sample population, 93 were determined not to have any of the three
point mutations. The most common polymorphism in this population was found to be at
the A719G position and this was not as expected, however with changes in population
demographics, shifts in mutation prevalence may occur.

The multiplex ARMS strategy designed in this work provides a fast, reliable, easy to
interpret and cost effective system to test simultaneously for the most prevalent point
mutations. Such improvements will be necessary if molecular screening for TPMT
polymorphisms is to be introduced into the clinical laboratory.
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Section 1
Introduction

1.1: Thiopurine methyltransferase (TPMT)
Thiopurine methyltransferase (TPMT) is a genetically polymorphic enzyme that
catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl compounds,
including widely used thiopurine drugs, 6-mercaptopurine (6-MP) and azathioprine.
These drugs are used to treat patients with neoplasia and autoimmune diseases, as well
as recipients of transplanted organs. A genetic polymorphism controls the level of
TPMT activity in human tissue (Weinshilboum, 1992). Patients with genetically low or
undetectable levels of TPMT activity develop severe myelosuppression when treated
with thiopurines, whereas “standard” doses of these agents may undertreat patients with
genetically high levels of the enzyme activity (Lennard et al., 1989). Now, with data
accumulated on molecular genetics and biochemistry relating to this enzyme there are
intriguing questions regarding the therapeutic significance of this polymorphic enzyme
as well as its biological functions and structural characteristics.

1.1.1: Discovery and characterisation of the TPMT Enzyme
Specific thiopurine S-methyltransferase activity has been found in mammalian, avian
and amphibian species and in certain Gram-negative bacteria (Remy, 1963). Thiopurine
methyltransferase (E.C: 2.1.1.67) is a cytoplasmic transmethylase that catalyses
methylation of sulphur atoms in aromatic and heterocyclic compounds using Sadenosyl-methionine as a methyl donor. Originally found in the kidney and liver of rats
and mice (Remy, 1963), it was subsequently shown to be present in most tissues, eg
heart, blood cells, placenta, pancreas and intestine (Krynetski and Evans, 1999). The
partially purified protein was initially characterised by Woodson and Weinshilboum
(1983).

TPMT has a molecular mass of 28-KDa, comprising 245 amino acids and is not metal
dependant (Krynetski and Evans, 2000). Derivatives of benzoic acid and thioxanthine
monophosphate, as well as certain drugs are inhibitors of TPMT catalytic activity
(Krynetski et al, 1995). No endogenous substrate is known for this enzyme , and its
biological role remains obscure. TPMT activity is higher in uremic patients, as well as
in newborns who do not have fully developed renal function (Me Leod et al, 1995).
The clinical and biological significance of these observations is unknown.

1.1.2 : Evolutionary conservation of TPMT
Clues to the origin of TPMT are evident from high degrees of homology between
TPMT sequences in distant species such as rodents, primates and bacteria. Comparison
of human, murine and rat TPMT amino acid sequences reveals significant similarity
(82% with 78 identical amino acids). For example Pseudomonas syringue has 45%
similarity with 33 identical amino acids, this shows clearly that this enzyme is
substantially conserved throughout evolution. Alignment of the amino acid sequences in
these three distant species (primate, rodent and bacteria) highlights conserved sequences
that presumably form catalytic/binding centres or maintain overall protein structure.
Moreover, the common inactivating mutations that result in loss of TPMT activity are
located within conserved regions of the polypeptide chain (Krynetski and Evans, 1999).

Following the isolation and sequencing of human TPMT cDNA (Honckel et al, 1993),
the screening of expressed sequence tags (EST) database led to the isolation of murine
and rat cDNA clones containing uninterrupted open reading frames (ORF) encoding an
amino acid sequence which was 82% similar and 78% identical to human TPMT
(Fessing et al, 1998). Murine TPMT protein is 90% identical to rat TPMT. About 70%
similarity was determined between human and murine TPMT mRNA sequences in the
5'-untranslated regions (UTR) with no significant homology in the 3'-UTR of mRNA.

1.2: Function of TPMT
Thioguanine and mercaptopurine are commonly used anti-cancer agents. Both
compounds are analogue of the nucleotide precursor guanine, with each bearing a
sulphydryl group attached to the 6-carbon position. The anti-cancer activity of these
drugs is thought to arise from the incorporation of these analogs into extending DNA
and RNA during replication and transcription, respectively. As the constituent cells of a
tumour are among the most frequently dividing cells in the body, they are most
susceptible to a therapy that interferes with DNA replication.

Both thioguanine and mercaptopurine are metabolised by Thiopurine Methyltransferase
(TPMT), by the addition of a methyl group to the sulfhydryl group of both drugs.
Methylation prevents the incorporation of these drugs into extending nucleic acid
polymers, limiting the drugs potency. Consequently, the dosage of drugs delivered to a
patient must exceed the patients ability to metabolically inactivate the drug. As there are

numerous polymorphisms of TPMT possessing disparate levels of activity, it is
important to tailor the drug dosage to the individual patient. Curiously, the metabolism
of anti-cancer drugs is the only known activity of TPMT. Presumably there is a
“natural” function but to date such a function remains unidentified.

1.2.1: Purine Metabolism
To understand how 6 metcaptopurine (6-MP) elicits its response the de novo synthesis
of purines must be reviewed. Synthesis of the first fully formed purine nucleotide,
inosine monophosphate (IMP) begins with 5-phospho-a-ribosyl-l-pyrophosphate
(PRPP). Through a series of ATP utilising reactions, tetrahydrofolate (THF) derivatives,
glutamane, glycine and aspartate this pathway yields IMP. The two enzymes glutaminePRPP amidotransferase and adenylosuccinate lyase (Figure 1.1) are those catalysing the
rate limiting step (Ellison, 1989).

IMP can then be biologically transformed to either adenosine monophosphate (AMP) or
glutamine monophosphate (GMP). GMP formation requires that IMP be first oxidised
to XMP using NAD^. The oxygen at position 2 is substituted by the amide nitrogen (N)
of glutamine at the expense of ATP. Similarly ATP provides the energy to convert IMP
to AMP. The amino group is provided by aspartate in a mechanism similar to that used
in the formation of a nitrogen atom at position 1 of the ring. Removal of the carbons of
aspartate as fumarate leaves the nitrogen behind as the 6-aminogroup of the adenine
ring. The monophosphates are readily converted to di- and tri-phosphates (Ellison,
1989).

Figure 1.1: De novo purine synthesis

1.2.2: Antimetabolites
The 6- thioguanine nucleotides inhibit the first commited step in the de novo purine
syntheis pathway (PRPP amidotransferase) by reaction with 5-phospho-a-ribosyl-lpyrophosphate (PRPP) via hypoxanthine-guanine pyrophoribosyltransferase (HG-PRT)
to form 6-MP riboside 5'-phosphate, more commonly known as thioinosine
monophosphate (TIMP) (Bo et al., 1999).

This has the effect of blocking the enzyme glutamine PRPP amidotransferase via a
pseudo-feedback inhibition in which TIMP mimics the regulatory action of adenine or
guanine nucleoside monophosphates (Christie et al., 1986). TIMP also blocks the
subsequent metabolism of inosinic acid (IMP) to adenylic acid by inhibiting
adenosylsuccinate synthase. Similarly, synthesis of guanine nucleotides is reduced by
inhibition of the oxidation of inosinic acid to xanthylic acid. TIMP is not incorporated
into nucleic acid, as such, but minor amounts are converted to thioguanylic acid, which
is incorporated into both RNA and DNA (see Figure 1.2).

Methylation prevents the incorporation of these drugs into extending nucleic acid
polymers by inhibiting or competing against the HGPRT pathway limiting the drugs
potency (Bo et al., 1999).

6-TU
XO

t

AZA---- ► 6-MP

1
6-MMP
ribonucleotides

Figure 1.2: Metabolic pathways of 6-meracptopurine (6-MP) metabolism.Azathioprine (AZA)
is rapidly converted to 6-MP by a non-enzymatic process. Initial 6-MP transformations occur
along competing catabolic (XO, xanthine oxidase; TPMT thiopurine methyltransferase) and
anabolic (HPRT, hyoxanthine phosphoribosyltransferase) enzymatic pathways. The latter
intracellular enzyme (dashed line) transforms the dmg into 6-thioguanine nucleotides (6-TG),
which have been shown to be the most important factor correlated with treatment efficacy.
TPMT converts the dmg into 6-methylmercaptopurine ribonucleotides (6-MMP). Patients
heterozygous for a mutant allele of TPMT will convert a higher proportion of the dmg into 6TG . This translates into a higher success rate, but with an increased risk of myelosuppression.
Patients with excessive TPMT activity, on the other hand, generate too little 6-TG with
overabundant 6-MMP levels. They are at increased risk of hepatotoxicity, and much less likely
to respond to thiopurine therapy.

1.3: Thiopurine Therapies

1.3.1: Azathioprine (AZA) and 6- Mercaptopurine (6-MP)
Azathioprine is a drag that was originally used to prevent rejection in organ transplant
patients. 6-Mercaptopurine (6-MP) is one of the metabolites of Azathioprine which is a
member of the thioguanine drug family. These are referred to as ‘steroid sparing’ drugs
because they facilitate the use of lower concentrations of steroid doses The methylation
of 6-MP by TPMT is illustrated in Figure 1.3.

6-Mercaptopurine has been in clinical use for over thirty years. 6-Meracaptopurine is a
purine antimetabolite, meaning it is a structural analogue of the naturally occurring
purine base hypoxanthine. 6-MP has both cytotoxic and immunosuppressive properties.
Cytotoxicity is thought to result from the incorporation of thiopurine metabolites into
cellular nucleic acids, while the immunosuppressive effects are secondary to inhibition
of the de novo purine ribonucleotide synthesis and interconversion (Lennard, 1992).
Most studies indicate that the thiopurines work at multiple body sites and that their
mechanism of action is as a result of combined effects at these different sites. 6-MP is
widely distributed in the body with the exception of the Central Nervous System (CNS)
where little drug is found (Gringauz 1997).

Once absorbed into the circulation AZA thioprine is rapidly converted to 6mercaptopurine. 6-MP is an inactive prodrug that requires intracellular anabolism to
nucleotides for cytotoxic activity. These nucleotides are uniquely incorporated into
DNA and RNA, resulting in cell death (Fairchild etal.,\9%6). 6-MP undergoes rapid
extensive catabolic oxidation to 6-thiouric acid in the intestinal mucosa and liver by the
enzyme xanthine oxidase. The anabolic transformation of 6-mercaptopurine into active
metabolites occurs intra-cellularly along the competing routes catalysed by thiopurine
methyltransferase (TPMT) and hypoxanthine phosphoribosyl transferase (HPRT) giving
rise to 6-methyl-mercaptopurine, 6-methyl-thioinosine-5'-monophosphate and 6thioguanine nucleotides respectively (Von Scoik et ai, 1985). Details of 6mercaptopurine metabolism are given in Figure 1.4.

Figure 1.3: Methylation of 6-MP by Thiopurine Methyl Transferase.

6-Mercaptopurine is methylated on the sulfhydryl group by thiopurine
methyltransferase (TPMT) through the addition of a methyl group to the sulfhydryl
group of this drug resulting in the formation of 6-methylmercaptopurine (6-MMP) with
subsequent oxidation of the methylated derivatives (Montgomery et al, 1997).
The immunosuppressive effects of AZA and 6-MP are mediated via their intracellular
conversion along two competing pathways (see Figure 1.2) to yield the nucleotide
metabolites 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP). 6-MMP is a
catabolic metabolite and is largely the product of the activity of the thiopurine
methyltransferase (TPMT) enzyme. Genetically determined variations in the activity of
TPMT can lead to differences in the likelihood of response to and toxicity from 6-MP
and AZA. (Yates et al., 1997).

SH

N''- "V ,-N
■>—OH

y
OH

6-Thioguanlne nucleotides
S Thiouric acid
XO*

N'

-N

N

NV-

"

r-' 'N

N ,0

NH2

CH,-'

H2PO4

TPMT

N' ,0

OH

CH2

GMeicaotopurine

MPK

CMPS

IMPDH

HPRT

SH

SH

SH

SH

SH

OH OH

H2PO,
^

6-Thioinosine

OH OH

6-Thioxanthoslne

0

-N

DPK

NH2

CH.-

----- ;

H2P2O7

OH OH

6 Thioguanosine

5 -monophosphate 5 -monophosphate 5-rr'onophosphate
SCH3

'/I. .--N

NHj

CH2-

H2PO4
^

V

SH

N 0 ■
C H 2—

-----

H2p'0-Q-----

OH OH

“

OH 0^

6 Thicguanosine G-Thioguanos ne
S -diphosphate

5 -flphcsoh^e

SCH3
-N

HPRT

N ■'

-N

6-Methylmercaptopurine CH2
H2PO4

r------

OH OH
G-Methythioi nosine
5 -monophosphate
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1.3.2: Clinical Use of AZA and 6-MP
Thiopurine drugs, azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-thioguanine (6TG), are widely used throughout medicine. Azathioprine is an immunosuppressant used
in the management of inflammatory bowel disease (IBD), autoimmune hepatitis,
rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA), dermatologic conditions and in transplantation medicine (McLeod and
Siva, 2002). The thiopurines are important components of most regimes used in the
treatment of childhood acute lymphoblastic leukemia (ALL) (Coultard et al., 2000).
Thioguanine is commonly used for treatment of acute myeloid leukemia (AML) and in
the treatment of some acute lymphoid leukemia (ALL) cases (McLeod and Siva, 2002).

1.3.3: Potential Drug Interactions
Potentially, TPMT activity can influence a number of compounds that could be co
administered with thiopurine drug. After a therapeutic dose of aspirin, plasma
concentration of salicylic acid are within the range for TPMT inhibition. Sulfasalazine
and its metabolite 5-aminosalicylic acid inhibit TPMT, and concurrent furosemide
therapy could influence the S-methylation of thiopurines. In addition, TPMT could
interfere with disulfiram treatment in alcoholism. TPMT S-methylates the
diethyldithiocarbamate metabolite involved in disulfiram activation. (Lennard, 1998)

1.4: Clinical Importance of TPMT Deficiency
TPMT deficiency is associated with severe hematopoietic toxicity when deficient
patients are treated with standard doses of mercaptopurine, thioguanine or azathioprine
(Lennard

a/., 1989). Importantly, this toxicity can be fatal. In contrast successful cases

of thiopurine therapy in TPMT deficient patients are exemplified by patients with acute
lymphocytic leukemia (ALL) successfully treated with 5-15% of the conventional dose
of 6-MP (Evans et al., 1991).
While the greatest risk of toxicity is clearly in patients with TPMT deficiency recent
data indicate that patients with intermediate cellular TPMT levels are also at significant
risk of toxicity when treated with thiopurine drugs (Aarbakke et a/., 1997).

It has been shown recently that TPMT-deficient or patients with intermediate TPMT
levels treated with mercaptopurine while receiving cranial irradation for CNS leukaemia
are at a significant higher risk of developing a secondary brain tumour (Relling et al.,
1999). A similar association has also been reported between inherited TPMT activity
and development of secondary acute myeloid leukaemia (AML) following treatment
with chemotherapy regimes incorporating topoisomerase II inhibitors and thiopurines
(Relling

1998).

On the other hand, low thioguanine nucleotide (TGN) concentrations in erythrocytes
(RBC) have been associated with higher risk of relapse in children with ALL treated
with anti metabolite -based chemotherapy protocols (Lennard et al, 1990). Due to the
fact that RBC concentrations of TGN are inversely correlated with TPMT activity, the
relation of TPMT activity and disease relapse was assessed in a group of 95 paediatric

patients. In this study, the subgroup of children with lower RBC-TGN concentrations
(below the population median) had significantly higher TPMT activity and importantly
a higher rate of leukemic relapse compared to those having TGN above the population
median (Lennard et al., 1990). It is now common to monitor RBC-TGN concentrations
in patients with ALL treated on protocols containing extensive 6-MP therapy, and it has
been suggested that transplant patients be screened for TPMT deficiency or TGN be
monitored during therapy (Me Leod et al, 1993). It has also been suggested that the
wide range of TPMT activity may be an important factor in determining long-term graft
survival in azathioprine treated patients (Chocair et al, 1992).

1.5: Genetics of TPMT

1.5.1: TPMT Gene Structure and Pseudogene
Isolation of TPMT cDNA was performed following partial purification and sequencing
of the protein (Honckel et al., 1993). Northern analysis of total RNA extracted from
different human tissues revealed three transcripts of 1.0,1.7 and 3.2 kb (Krynetski et
a/., 1995) due probably to varying lengths of their 3'-UTR ( Szumlanski et al, 1996).
The clinical importance of tissue specific expression of TPMT mRNA in humans has
not been established, but both Northern analysis and immunostaining studies
consistently reveal the highest mRNA level to be in the kidney and liver. (Krynetski and
Evans, 1999).

The human chromosomal TPMT gene was isolated by PCR screening of two different
human genomic libraries using intron and exon-specific primers (Szumlanski et al.^
1996). TPMT was isolated from a PACl library and consists of 10 exons and 9 introns
spaning 25-kb whereas TPMT gene isolated from chromosome 6 specific library was 5kb longer due to differences in intron 8 (Szumlanski et al, 1996). Fluorescence in situ
hybidisation localised TPMT to chromosome 6p22.3 (Krynetski et al, 1996). In
addition, a processed pseudogene was mapped to 18q 21.1 (Lee et a/., 1995).

The human TPMT promoter does not contain a TATA box or CCAAT element
consensus sequences. One major and two closely located minor transcription start points
were identified in Hep G2 cells. DNase 1 footprinting analysis documented that Spl
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binds to the TPMT promoter and is important for constitutive activity (Fessing et al,
1998).

A variable number of tandem repeats were initially discovered in the proximal TPMT
promoter region that determines the level of basal TPMT gene expression (Fessing et al
1998) .This polymorphic locus within the promoter region of TPMT was also observed
in a study involving 54 unrelated European individuals (Spire-Vayron de la Moureyre et
al, 1998) .Five alleles containing 4-8 tandem repeats in the promoter region were
characterised each consisting of 17 or 18 bp units with putative binding sites for
transcription factors.

1.5.2: Genetic Polymorphism of TPMT
The genetic polymorphism of TPMT activity in humans was discovered in a study of
TPMT activity in RBC. Subsequent family studies established the autosomal
codominant pattern of inheritance of TPMT in humans with about 10% of the
population having intermediate activity (5-10 U/ml per RJBC) and one in three hundred
inheriting TPMT deficiency ( '5 U/ml per RBC) (Weinshilboum and Sladek, 1980).
The initial finding of Weinshilboum and Sladek (1980), indicating the hereditary nature
of TPMT deficiency in humans, was further substantiated by identification of
inactivating mutations in the human TPMT gene (Otterness et al, 1998). Currently,
eight variant alleles for low level of enzymatic activity have been reported. Like mutant
alleles of other polymorphic enzymes, these alleles contain point mutations leading to
amino acid substitutions (TPMT *2, *3 A, *3B,*3C, *3D, *5, *6 *7,* 8)and in one case
formation of a premature stop codon (TPMT *3D) or destruction of a splice site (TPMT
*4). Consequences of amino acid substitutions in alleles *2 *3A *3B and *3C have
been extensively characterised in both in vitro and in vivo experiments. The wild type
allele is designated TPMT *1; the allele with T474C silent mutation not leading to any
change in enzymatic activity is designated *1S (Yates et al, 1997).
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Table 1.1: Summary of the allelic variants of TPMT and their associated molecular
defect, exon position and amino acid substitution.
TPMT Variants
TPMT*2
TPMT* 3 A

TPMT*3B
TPMT*3D

TPMT*4

Molecular Defect
G238

C Transversion

G460 *4 A Transition

Exon

Codon

Effect

V

80

Ala

Pro

VII

154

Ala

Thr

A719

G Transition

X

240

Tyr -> Cys

G460

A Transition

VII

154

Ala

V

98

Glu -> Stop

G292 -> T Transversion

Thr

G460

A Transition

VII

154

Ala-> Thr

A719

G Transition

X

240

Tyr -> Cys
Dismpts final
nucleotide of
intron at splice
sequence site
Leu
Ser

G
A Transition at
intron 9/exon 19 splice
Junction

IX/X

TPMT*5

T146

C Transition

IV

49

TPMT*6

A539

T Transversion

VII

180

Tyr

TPMT*7

T681

G Transversion

X

227

His “♦ Glu

TPMT* 8

G644

A Transition

X

215

Arg

12

Phe

His

Figure 1.5: A genetic map summary of the allelic variants at the human thiopurine Smethyltansferase (TPMT) locus in diagramatic form. Boxes depict exons in the human
TPMT gene. White boxes are untranslated regions, and black boxes represent exons that
contain an open reading frame. Hatched boxes represent exons (to the left of each line)
that contain mutations that result in changes in amino acids. The dashed box represents
exon 2, which was detected in one of 16 human livers (adapted from Szumlanski et
al.,1996).

45

TPMn
(wild type)

112

1S4

93

133

53

75

86 45

2070

-CK>Di-i-B III! g
ATG

TPKinS
(silen!)

|_j

.

.HIB B B I B i i g
'

ATG

TPt^T'IA

I
T474C

■■ ■!■■■■
C(-178)T

TPK/IT'2

-ch:h:b-5-i i
gISc

i

b b

b

(AJa-»Pro)
TPMT‘3A

ATG

TPMT-3B

B B I f-H
G460A
(Ala-»Thf)

-ch;hj-b

b

A719G
(Tyr.»Cys)

I i-i-i-B
G460A
(Ala-»Thr)

TPfJT'3C

~~D-;..'HIB-B-B I I i i
A719G
(Tyr4Cys)

TPUT-3D

G292T
G460A
(Glu-»Stop)
TPMT'4

A719G

-TO£H-B B 11 ■ I g
ATG

TPMrs

I
G4A

HKKJ-p-B I ■ 11 g
T1«C
(Leu4Ser)

TPMre
ATG

B B I ■ f-i-a:
A539T

(Tyr-»Ph«)
TPMT-/

-[>i:}-CB-B' ■ I ■ ■ I i
ATG

TPMre

T
TeaiG
(Hi*-»Glu)

-OiVKJ B B ■ I M ■ ^
ATG

Ge44A
(Ayg-fHls)

13

1.5.3: Population Studies
Population studies in Caucasian, East and West African, African-Americans, Chinese,
Japanese and Southwest Asian populations showed significant ethnic differences in the
distribution of TPMT alleles (Me Leod et al, 2000). For example, Southwest Asians
(Indian, Pakistani) have a lower frequency of TPMT mutant alleles and all alleles
identified to date are TPMT *3A (Me Leod et al., 2000). In contrast, East and West
African populations have a frequency of mutant alleles similar to that of Caucasians but
all mutations in the African population are TPMT *3C. Furthermore, TPMT *3C
accounts for approximately 70% of mutant TPMT alleles in African-Americans, but for
only about 5% of mutant alleles in Caucasians. TPMT *3 A accounts for more than 80%
of mutant alleles in Caucasian populations in the US and in Northern Europe, but for
only approximately 17% of mutant alleles in African-Americans. Thus, Caucasians,
Asians, Africans and African-Americans share the same TPMT mutations, but exhibit
significant ethnic differences in allele frequencies.(Me Leod et al, 2000).
Anthropologically, these findings indicate that A719G (Figure 1.5) was the first TPMT
mutation to arise in humans, because this is the only mutation observed in both Chinese
and African populations. It occurs in Caucasians either alone or in combination with
G460A in TPMT *3A and *3D (Figure 1.5). Thus, the ancestral TPMT *3C allele
probably acquired the G460A after divergence of African and non-African populations.
A clinically important consequence of this observation is that the same molecular
methods can be used to diagnose TPMT deficiency and heterozygosity in these different
ethnic groups (Krynetski and Evans, 1999)
Six additional TPMT mutant alleles have been reported to date (TPMT *3D, *4, *5, *6,
*7, *8), but most of these have been observed in only a single individual and may be
‘private’ mutations (Krynetski and Evans 1999). Figure 1.6 illustrates the global
distribution location of the most prevalent mutations.
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Figure 1.6: Distribution of TPMT alleles on a global scale (adapted from
wwyN.

stj ude.org/deparrments/tpmtslide20. htm)
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1.6: Diagnosis of TPMT Deficiency in Patients
Introduction of a radiochemical extraction assay in 1978 originally described by
Weinshilboum et al, facilitated rapid screening of large populations and with some
improvements this method is currently used for monitoring TPMT activity in clinical
studies (Krynetski and Evans, 1999). In this assay erythrocytes are used as surrogate
cells for drug metabolising tissues and a strong correlation between TPMT activity in
erythrocytes and other tissues has been established (Woodson et al, 1982).

Several variants of HPLC assays have been developed that allow the determination of
methylated thiopurines formed in the course of the TPMT catalysed reaction (Krynetski
et al., 1995). One factor that can influence inter-laboratory differences of TPMT assay
is impurities in commercially available thioguanine, causing inhibition of TPMT
(Kroplin et al, 1999). Also laboratory differences in assay conditions, such as the
amount of co-substrate (SAM) used can cause significant differences in TPMT activity.
While it is possible to diagnose TPMT activity in erythrocytes, this measurement may
not reflect constitutive activity of patients who received donor erythrocyte transfusions
within the past two or three months. To overcome this several DNA molecular based
methods have been developed that are unaffected by donor erythrocytes. DNA-based
methods to diagnose prospec ively TPMT deficiency offer a clinically important
strategy to minimise risk of potentially life-threatening hematopoietic toxicity in
patients treated with these drugs (Seidman, 2003).

1.6.1: Enzyme assay
RBC TPMT activity was measured using a radiochemical assay, as originally described
by Weinshilboum et a/.,(1978) and modified by Me Leod et al, (1995). This assay
involves incubation of red cell lysates with [^"^C-methyl] -S-adenosylmethionine
extracted into a toluene/ispamyl alcohol mixture and the amount formed
measured by scintillation counting. Counts obtained from blank tubes (no 6mercaptopurine added) were subtracted from those with 6-MP added to correct
for non-specific methylation. One unit of activity was defined as the amount of
enzyme required to produce 1 nmol/h methylmercaptopurine at 37°C.
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An obvious limitation to the widespread use of the assay is the significant biohazard
associated with the handling and disposal of volatile organic solvents
contaminated with radioactive waste (Coultard et al, 2000).

1.6.2: HPLC analysis
A high performance liquid chromatographic (HPLC) assay system was previously
developed to measure TPMT activity, using a radioactive substrate. However, due to the
legal and safety restrictions on the handling of radioactive material this assay was not
widely used. The original format was modified with the establishment of a HPLC assay
system to determine TPMT activity using 6-MP as a non-radioactive substrate. This
assay is sensitive, safer and inexpensive. It enables screening for TPMT activity in
patients scheduled for 6-MP treatment (Nishida et al, 2002)

1.6.3: Genetic Screening /Testing
The rapid advance of the Human Genome Project and the development of technologies
such as gene chips, automated gene-sequences and Bioinformatics software promises to
bring a new era of genomics to medicine. Among the goals of integrating the large
volumes of genomic information with the practice of medicine are
1) Identification of patients with hereditary predisposition to disease.
2) Development of gene-based therapies
3) The individualisation of drug therapy based on an individuals genetic
information.
The third application is generally referred to as pharmacogenomics and it will be one of
the first tangible benefits resulting from the Human Genome Project.

The concept underlying pharmacogenomics is that response to drug therapy is variable,
in part because of genetic variation. Genetic variations that are common are known as
polymorphisms. More than one-third of human genes have been found to be
polymorphic (Brookes, 1999). A change in the nucleotide sequence of a gene can lead
to a change in the amino acid sequence at the protein level and altered enzymatic
activity, protein stability and binding affinities. Genetic variation can thus affect drug
efficacy and safety when the mutations occur in proteins that are drug targets (Me
Carthy and Hilfiker ., 2000).

!7

Treating TPMT-deficient patients with standard doses of mercaptopurine, thioguanine
or azathioprine can be fatal, but such patients can be successfully treated without severe
toxicity if the dose is properly adjusted (Seidman, 2003). The use of pharmacogenomics
to individualise drug therapy offer the potential to improve drug effectiveness, reduce
adverse side effects and provide cost effective pharmaceutical care. Although TPMT
deficiency can be diagnosed by measuring TPMT activity in erythrocytes, such
measurements do not reflect constitutive activity if patients received transfusions of
RBCs within the past two or three months. Molecular genetic methods are not affected
by donor erythrocytes. Therefore molecular methods provide a more robust approach
with which to diagnose patients with TPMT deficiency or heterozygosity at the TPMT
gene locus.

In one study entitled 'Practical pharmacogenetics’ the cost effectiveness of screening for
thiopurine methyltransferase polymorphisms in patients with rheumatological
conditions treated with azathioprine were assessed (Marra et al., 2002). It was
concluded that the introduction of PCR testing to identify TPMT polymorphisms prior
to AZA treatment represents good value in certain health care settings.
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1.7 Modern Strategies for Detection Of TPMT Polymorphism

1.7.1 Polymerase Chain Reaction
1.7.1 ■ 1 Overview of the Polymerase Chain Reaction (PCR)
The polymerase chain reaction is an in vitro technique that amplifies specific segments
of DNA. Following its development in 1985 by Kary Mullis (Mullis et al., 1986 , Mullis
et a/., 1987), the number of applications reported for PCR together with novel design
modifications has grown exponentially (Fanning and Gibbs, 1997). Polymerase chain
reaction is capable of very high sensitivity of molecule detection and is therefore a
favourable practical technique in that it obviates the need to use hazardous radio
isotopic detection systems that were more commonly used.

The in vitro enzyme-mediated amplification of target DNA by PCR is comprised of a
repetitive series (Figure 1.7) .A single cycle involves three steps:
1) duplex template DNA denaturation
2) annealing of oligonucleotide primers that hybridise to opposing
strands close to the region of interest and
3) extension of annealed primers by a thermostable DNA polymerase

A summary of the conditivms fc^" step 1) through 3) is given in Table 1.2
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Figure 1.7: Overview of the PCR reaction (Diagram modified from Fanning and Gibbs,
1997)
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Table 1.2: Summary of the general parameters used during the three steps in the PCR
cycle.
Step

Typical Reaction Parameters

Denaturation

Initially, temperatures of 92-96°C for 3-5 min ensures DNA is
completely denatured. In subsequent steps, denaturation lasts
for about 1 min to prevent loss of enzyme activity.

Annealing

Primers anneal to complementary sequences at temperatures
ranging from 40-70°C. This temperature is typically 5°C below
the Tmf (melting temperature) of the target sequence.

Extension

Taq DNA polymerases extend annealed primers in a 5' to 3'
direction to form nascent DNA strands. Optimal temperatures
for the enzyme are between 70-75°C .

Tmf may be estimated theoretically by Sugg’s equation:
4(G+C)+2(A + T).......where A, T,G and C represent the number of
respective bases in the target sequence.
If PCR was to be 100% efficient, one target molecule would accumulate to 2" after n
number of cycles used. In practice, 20-40 cycles are commonly used.

There is no one ‘standard’ reaction mixture that is suitable for all PCRs. Some
reagents/materials are of course essential, but the target sequences differ in length, base
composition and arrangement and therefore modifications in reaction conditions are
often necessary. Table 1.3 provides a summary of the reagents that are used for
successful PCR reactions.

Cork Institute of Technology

Table 1.3: Summary of the reagents used for successful PCR reactions
Reagent/Material
Template DNA

Properties
Of good quality when extracted from the buffy coats of centrifuged
blood samples (5-10 fold DNA yield than from whole blood) using
commercial DNA extraction kits.

Oligonucleotide Primers

These are often between 18-30 bases in length with similar GC content.
Important in primer design is correct base pairing at the 3’-end.
Deliberate modifications at the 5'-ends of primers may be used to aid
mutation detection.

Thermostable

Essential for 5'

^ 3' exonuclease activity. Optimal concentrations

DNA Polymerase

range from 1-2.5 units per 100

|Lil

reaction volume. Taq DNA

polymerase from the thermophilic bactenum, Thermus aquaticus^was
used in this project. Many others are available from other organisms
such as Thermococcus litoralis, Thermus thermophilus or Pyrococcus
furiosus each with their own characteristics (Fanning and Gibbs, 1997).

MgCh

Important for enzyme activity-it helps to increase the Tm of dsDNA
and foims soluble complexes with dNTP that are essential for dNTP
incorporation. Concentrations of about 1-4 mM are usually optimal.

dNTPs

Essential substrates for incorporation into nascent DNA strands.
Optimal concentrations range between 50-200 pM of each dNTP.

PCR Buffer

The^e may vary greatly but usually contain Tris-HCl and KCl.
Functions can include maintaining pH at optimal levels, facilating
primer annealing, aiding dNTP incorporation and fidelity of the
polymerase enzyme.

Some mutation detection and identification techniques depend upon the actual PCR
itself, while other require analysis of the amplification products The way in which PCR
and various post amplification techniques were applied in this project will be outlined.

1.7.2: Restriction Fragment Length Polymorphism (RFLP) analysis
Restriction enzymes are endonucleases that are derived from bacteria. They have the
ability to cleave both strands of double stranded DNA within particular recognition
sequences. Occasionally, mutations create or destroy restriction endonuclease target
sites and this enables simple diagnosis of the mutation by gel electrophoresis following
enzyme digestion of any PCR product. DNA fragments of different sizes generated by
digestion with the appropriate enzyme (depending on the presence or absence of a
mutation) gives rise to the term “Restriction Fragment Length Polymorphism” analysis.

1.7.2.1 Principle of PCR-RFLP
A combination of PCR and RFLP analysis can be used to detect a genetic
polymorphism. Figure 1.8 provides a schematic representation of the polymerase chain
based reaction (PCR) method followed by the post amplification strategy of Restriction
Fragment Length Polymorphism analysis (PCR-RFLP) for detection of the TPMT
polymorphism G460A as described by Krynetski and Evans (2000). This strategy
facilitates the identification of heterozygous, homozygous and/or normal genotypes.
Briefly, the forward and reverse primers are designed to amplify a PCR product (365
bp) which after purification is digested with Mwol. The wild type genotype contains the
restriction endonuclease recognition site and consequently produces products of 98 bp
and 267 bp. The mutant genotype does not contain the recognition site for the
endonuclease and therefore remains undigested. The heterozygous sample contains both
and therefore contains the undigested 365 bp (mutant allele) product along with the
digested products 98 bp and 267 bp.
PCR-RFLP has also been described to detect the A719G (Krynetski and Evans, 2000)
and the rare TPMT mutations (Hiratsuka et al., 2002). The concept in these analyses is
as for G460A. However, in some cases the mutant allele (and not the wild type)
contains the restriction site and is consequently digested.
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Detection of the TPMT*3B Polymorphism: PCR-RFLP Strategy

Mwo1 Digestion
Normal
Heterozvaote
[Homozygous]

AbNormal
[Homozygous]

365 bp
269 bp
98 bp

Figure 1.8: PCR-RFLP strategies to detect TPMT*3B (G460A)
polymorphism. See also Figure 1.5 and Table 1.1 (- and+
denote pre and post restriction enzyme, respectively.
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1.7.3: Amplified Refractory Mutation Detection Systems (ARMS)
Any known mutation in genomic DNA may also be detected using a system known as
ARMS (Newton et a/., 1989). This simple, rapid and reliable technique has the
advantage over other types or analysis involving PCR in that it allows genotyping
solely by inspection of PCR reaction products after conventional agarose gel
electrophoresis.

1.7.3.1 Principle of ARMS
ARMS works on the principle that oligonucleotides with a mismatched 3-nucleotide
will not function as primers in a PCR reaction under appropriate conditions. By using
two forms of a primer that are allele specific at the 3'-nucleotide, a limited number of
results are possible. The ‘normal’ form of the primer is refractory to PCR on mutated
DNA and conversely, the ‘mutated’ form of the primer is refractory to PCR on ‘normal’
DNA. In this way, the requirement for complex post-amplification procedures is
eliminated.
This strategy was previously described by Kiymetski et al., (1996) for the direct
detection of the G238C polymorphism. Figure 1.9 provides a schematic illustration of
this approach.

25

Detection of the TPMT*2 Polymorphism: ARMS

Intron 4

Intron 5
P2W
P2M

O

<C:

O.P2C

Amplification

256 bp amplicon

V
Normal
[Homozygous]

P2W+P2C P2M+P2C

256 bp

Heterozyqote

P2W+P2C

P2M+P2C

Abnormal
[Homozygous]

P2W+P2C

P2M+P2C

C>

Figure 1.9: ARMS detection of TPMT*2 (G238C). For each individual two PCR
reactions are carried out using the primer pairings indicated.Genotypes are
determined directly following examination of the gels.
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1.7.4: Gene Scan Analysis
In addition to conventional agarose gel electrophoresis, fluorescently- labelled PCR
products can be detected using automated systems such as the ABI Prism"^^ GeneScan
technology. This flouorescence detection system permits the labelling of DNA
fragments with up to three differentially coloured fluorescent dyes with a fourth dye
colour for labelling an internal size standard. The versatility provides an iseal system for
detection of numerous PCR products such as those generated from multiplex analysis
and the results obtained using such approaches can be interpreted easily (Versalovic et
al., 1995, Cotter

a/ ., 1998). In addition, the inclusion of internal standards permits

accurate sizing of PCR products.
In this project, conventional agarose gel electrophoresis and automated GeneScan
analysis were used to detect the multiplex TPMT PCR products.

1.8.: Other mutation detection Strategies
Analysis of TPMT mutations in this project involved PCR-RFLP and ARMS assays. In
this section, other mutation detection/screening strategies are briefly described.

1.8.1: Single Stranded Conformational polymorphism (SSCP) analysis
PCR-based SSCP is a very simple and sensitive technique used to detect point
mutations. First described by Orita et al, (1989), it has become one of the most widely
used mutation scanning methods. The principle of SSCP analysis is based not only on
the length of single DNA (ssDNA) but also on the secondary structure (conformation)
assumed by the ssDNA undergoing electrophoresis using non-denaturing additions.

SSCP analysis is peculiar in that a non-denaturing polyacrylamide gel (PAGE) is used.
Following PCR amplification of wild type and mutant target DNA, the products are
denatured and electrophoresed through the gel. The non-denaturing property of the gel
facilitates the development of intramolecular interactions within the migrating single
strands to occur. Consequently, the ssDNA molecules from each denatured PCR
product assume a three-dimensional conformation that is dependant upon the primary
sequence of the DNA. Single base changes are sufficient to change the secondary
structure resulting in a mobility shift. Mutations are therefore visualised on gels by
differential migration when compared with wild-type migration patterns. It is important
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to note that SSCP analysis simply detects mutations. Subsequent DNA sequencing is
necessary to identify and characterise any mutation detected as a fragment shift on a
PAGE gel.

A single-strand conformation polymorphism (SSCP) analysis of the TPMT gene
amplified by polymerase chain reaction (PCR) was developed to detect mutations in
thiopurine S-methyltransferase gene (TPMT) (Spire et al, 1998). In a clinical study it
was concluded that the PCR-SSCP strategy could be advantageously used to fully
characterise the extent of allelic variation at the TPMT gene locus in populations and
thus improve our understanding of the genetic polymorphism of TPMT activity, which
has considerable consequences for the toxicity and efficacy of therapeutically important
and widely used drugs (Spire et al, 1998).

Wild- type sense strand

Wild-type antisense strand

Mutant antisense strand

Figure 1.10; Different conformations of DNA in SSCP analysis

For successful SSCP analysis amplified fragments should be small, typically <300 bp,
as the sensitivity of detection decreases as fragments increase in size. On average the
technique detects between 70% and 95% of point mutations (Grompe,1993)
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Detection of the products on gels can be performed using several methods including
silver and ethidium bromide staining and using fluorescence and radiolabels. However,
interpretation of gel patterns can be complicated. In addition to the single stranded
fragments, faster migrating bands of double stranded DNA (dsDNA) are often detected.
The non-denaturing conditions of the gel allow some reannealing of single strands.
These are not significant and can in fact aid in mutation detection by the presence of
‘heteroduplex shifts’.

Important considerations for successful SSCP include: maintaining a constant gel
temperature, using optimal cross-linking ratios between acrylamide and bisacrylamide,
using correct acrylamide concentrations, correct length of time for electrophoresis (can
depend on fragment length), running of a dsDNA control to allow distinction between
ssDNA and dsDNA bands.

1.8.2: Heteroduplex Analysis
Double stranded DNA molecules that contains a mismatch are known as
heteroduplexes. These can be separated from homoduplexes on gels and therefore can
be used as a mutation detection system (White et al, 1992; Grompe et a/., 1993).

If mutant and wild type DNA sequences are present in a PCR reaction, molecules may
form that are identical to the original ones (homoduplexes) or hybrid molecules
(heteroduplexes) during the late cycles. Upon analysis using regular polyacrylamide
gels, homoduplexes migrate according to size, but heteroduplex migration differs
(Nagamine et al, 1989). This may be due to the production of a kink or mismatch
bubble. This method is simple to use and has similar sensitivities for mutation detection
as SSCP analysis.
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1.8.3: Chemical Mismatch and RNase Cleavage
These techniques are similar in that heteroduplexes are involved. As the name suggests,
in Chemical Mismatch Cleavage (CMC) chemicals such as hydroxylamine and osmium
tetroxide react with mismatches in a DNA heteroduplex (Cotton et al .,1988; Grompe et
a/.,1989; Forrest

a/., 1991;Grompe et a/.,1993). This chemically labelled DNA is then

cleaved by piperidine at the site of the mismatch and electrophoresis on polyacrylamide
gels detects mutations on the basis of DNA fragment sizes.

In RNase cleavage an RNA DNA heteroduplex is the target of the enzyme RNase.
Amplified DNA from a PCR reaction is denatured and annealed with a single stranded
RNA riboprobe. The RNase enzyme recognises the single stranded RNA at the point of
mismatch and cleaves the RNA. Variations in the generated fragment sizes indicate the
presence and location of mutations.

1.8.4: Denaturing Gradient Gel Electrophoresis (DGGE)
This is a highly reliable method for mutation detection with a mutation detection rate
close to 100% in PCR products up to 600 bp in length (Gandrille et a/., 1992;
Grompe, 1993; Hawkins, 1997).

The DGGE system is composed of a gel that contains an increasing concentration
gradient of denaturant (urea and formamide). As fragments migrate down the gel,
strands progressively dissociate once they reach a critical denaturant concentration
(Lerman et a/., 1987). The ‘melting’ leads to a reduction in electrophoretic mobility.
Since the melting temperature (Tm) in particular domains will differ between wild type
and mutant alleles, this will be reflected in electrophoretic band patterns.

The sensitivity of DGGE is enhanced if heteroduplex DNA between wild type and
mutant sequences is used for analysis. ‘GC-clamps’ are often included in the primer
design to ensure that the amplified sequence has a low dissociation temperature and
avoids non-detection of mutations in the highest melting domains (Sheffield et al,
1989).
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1.8.5: Dot Blots

This technique is very useful for identifying the presence of known mutations. It is also
excellent for genotyping many PCR samples for a single mutation. Dot blotting is
sometimes referred to as Alleie-Specific Oligonucleotide Hybidisation. Usually PCR
product is fixed to a nylon membrane by means of a vacuum dot blotter.
Oligonucleotide probes, labelled with

ATP molecules at the 5'-end (or some

other reporter group such as digoxigenin), that are homologous to the wild type or
mutant alleles are then added to the membrane (Hawkins, 1997). Similar to Southern
blotting, genotyping can be subsequently carried out using autoradiography or non
radioactive detection strategies. A schematic illustration of Dot Blots is shown in Figure
1.11.

PCR products dotted onto nylon membrane

Homozygous wild type sample

O

Heterozygous sample
Homozygous mutant sample

Hybridise to oligoucleotide probe

Wild-type oligo probe

Mutant oligo probe

Figure l.lliTvpical Dot Blot genotyping mechnaism
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This method can be altered so that PCR product from individuals may be used as the
‘probe’ and the oligonucleotides are immobilised on the nylon membrane. This is
known as a‘reverse dot-blot’.

Dot blots may be of great value in terms of a screening test mutations implicated in
predisposition for disease, by facilitating simple, rapid and cost effective genotyping of
several mutations simultaneously.

1.8.6: 5'-Nuclease Activity, Fluorogenic Probes and the ‘TaqMan’ assay
More recent advances in PCR technology include utilisation of the 5'-nuclease activity
of 7hr^_DNA polymerse and fluorogenic oligonucleotide probes in combination.
In 1991, Holland et al., demonstrated that cleavage of a target probe during PCR by the
5'-nuclease activity of Taq DNA polymerase could be used to detect amplification of a
target-specific product. Following the development of fluorogenic probes (Lee et al.,
1993) the Perkin Elmer Applied Biosystems Corporation designed the Taqman® assay
system that uses these two recent developments for PCR analysis.

lourogenic 5' Nuclease Chemistry
olymerization

Cleavage

Strand Displacement

Polymerization Completed

fttWMO

9,
wo fluorescent dyes, a reporter (R)
nd a quencher (Q), are attached to
'e 5' and 3' ends of a TaqMan* probe.

When both dyes are attached to
the probe, reporter dye emission
is quenched.

3.

During each extension cycle, the
Taq DNA polymerase cleaves the
reporter dye from the probe

Cl

_®.

Once separated from the quencher,
the reporter dye emits its characteristic
fluorescence.

Figure 1.12: Representation of the forklike-structure-dependent, polymerizationassociated, 5 to the 3 nuclease activity of r<3^_DNA polymerae acting on a fluorogenic
probe during one extension phase of PCR. (Diagram taken from Perkin Elmer Applied
Biosystems, Manufacturers Literature, Warrington, U.K.

32

The advantages of this system are valuable from a practical point of view. Non-specific
amplification due to mispriming or primer-dimer artefact does not generate fluorescent
signal. Different reporter dyes may be used which allows the possibility of amplification
of two distinct sequences in a single reaction.
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Section 2
Materials and Methods

Experimental Objectives

•

Extraction of high quality DNA from 100 patient samples.

•

Screen the sample for the three most prevalent TPMT mutations i.e. G238C,
A719G and G460A using the previously described molecular methods of
ARMS for G238C and PCR-RFLP for G460A and A719G.

•

Design of allele-speeifie oligonucleotides for G460A and A719G assays.

•

Optimisation and validation of a multiplex ARMS strategy, for simultaneous
deteetion of the three most prevalent TPMT mutations.

•

Comparison of the results obtained for the sample population using the novel
ARMS system with those obtained using the conventional molecular
approaches.

•

Analysis of the multiplex ARMS results using fluorescent GeneScan analysis.
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Section two is divided into two parts:
Section 2.1: Materials describes all samples, chemicals, reagents buffers and
equipment necessary to complete the experimental work.
Section 2.2: Experimental Methods describes in detail the methodologies employed to
achieve the objectives set out in this project.
2.1:Materials
2.1.1: DNA Extraction
2.1.1.1 :Blood samples
One hundred blood samples were obtained from patients attending the Bon Secours
Hospital, Cork. Blood samples were obtained by venipuncture and collected in
trisodium citrate-containing vacutainer tubes. In order to gain ethical approval for this
study no clinical data was accessible with the patient test samples.

2.1.1.2: Control DNA samples
Control DNA samples were obtained from St. Judes Children’s Research Hospital,
Memphis, Tennessee and Mayo Institute, Rochester, Florida. These controls were
heterozygous for the following mutations TPMT*5, TPMT*6, and TPMT*8.
2.1.1.3: DNA extraction from whole blood
DNA was extracted from the buffy coat moiety of centrifuged whole blood samples
using a QIAamp Blood Kit (Qiagen Ltd., West Sussex, UK).
The kit is supplied with spin columns, 2 ml collection tubes, reagents including
Qiagen protease, solution ALl and AL2, and buffers AW and AE.
For optimised results the following steps were taken in accordance with manufactures
instructions prior to using the kit:
•The lyophilised Qiagen protease was stored at -20°C.
•Buffer AL was prepared by adding the contents of solution AL, to solution
AL2 mixing well and storing in the dark at room temperature.
•Ethanol (96-100% (v/v)) was added to buffer AW as directed.
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2.1.2: Polymerase Chain Reaction

2.1.2.1 PCR buffers
Table 2.1 below shows details of the four PCR buffers used in the project. The PCR
reaction for which they were used, their supplier and their respective compositions are
shown.

Table 2.1: PCR Buffers
Supplier
Buffer

PCR Reaction^

Composition

lOX Taq Buffer

Multiplex PCR

100 mM Tris-HCl pH

Sigma Poole, UK

8.3,500mM KCl, 15mM
MgCb and 0.01% (w/v)
gelatin
Buffer J

Buffer N

lOX Taq Buffer

Invitrogen Life

G460A PCR RFLP,

300mM Tris-HCl, 75mM

Technologies, USA

G460A ARMS

ammonium sulphate,

Assay

lOmM MgCl2,pH 9.5

Invitrogen Life

A719G PCR RFLP,

300mM Tris-HCl, 75mM

Technologies, USA

A719G ARMS

ammonium sulphate,

Assay

lOmM MgCb, pH 10.0

Promega, Madison,

G238C ARMS

lOOmM Tris-HCl pH 9.0,

WI

Assay,

500mM KCI and 1%

TPMT*4,*5,*6,*7,*8

(w/v) Triton X-100

PCR RFLP

t Details of the oligonucleotide primers in each of the PCR reactions are shown in
Table 2.3 and Table 2.4.
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2.1.2.2: Tap Polymerase Enzymes
The Tag polymerase enzymes used in the PCR assays are shown in the following
table.

Reagent

Supplier

Enzyme Activity

Storage
Conditions

Tag DNA polymerase

Promega

5U/pl

Stored @ -20°C

Amplitaq DNA

Applied Biosystems

5U/pl

Stored @ -20°C

Sigma Poole UK

5U/pl

Stored @ -20°C

polymerase
Sigma Tag DNA
polymerase

2.1.2.3 Deoxynucleoside Triphosphates fdNTP) mixtures
Individual deoxynucleoside triphosphates (dATP, dCTP, dGTP and dTTP) were
supplied by Promega at a concentration of 100 mM each.
Two working solutions concentrations of dNTPs were prepared as follows:
•1.25 mM concentration was prepared by adding 2.5 pi of each dNTP to
190 pi of sterile dH20
•2.5 mM concentration was prepared by adding 5 pi of each dNTP to 180 pi of
sterile dH20.
Stock dNTPs and working solutions dNTP mixes were stored at -20°C.

2.1.2.4 Magnesium Chloride (MgCl?)
MgCb (25 mM) was supplied for use with the Promega Tag buffer. All other PCR
buffers contained MgCb (see Table 2.1).

2.1.2.5 Oligonucleotide Primers for PCR
Oligonucleotide primers were synthesised by Oswel (Hampshire, UK) or by MWG
Biotech (Ebersberg, Germany), purified by HPLC and supplied in
(a) lyophilised form (Oswel) or
(b) reconstituted in 1 ml of sterile dH20 (MWG Biotech)
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Primer concentrations were calculated using data supplied by the manufacturer as
follows
Cone, of primer (pmol/ml) = quantity (pg/pl) / Molecular weight of primer (pg)
Working stocks for individual primers were prepared. Small aliquots of stock primer
were prepared in 1.5 ml eppendorf tubes and stored at -20°C

The PCR primer sets used for detection of TPMT mutations in this project are
summarised in Table 2.3.

38

Table 2.3 Primer sets used for TPMT mutation detection. (Mismatch bases are in red)
Mutation

Primer

Sequence

Type
*G238C

Amplicon

Reference

Size (bp)
P2W (Forward)

Transversion

5'-GTA TGA TTT TAT GCA

254

Yates ^

2000

365

Yates ^

2000

293

Yates ^

2000

361

Hiratsuka ^ ^.,2000

138

Hiratsuka ^ ^.,2000

230

Hiratsuka ^ ^.,2000

378

Hiratsuka ^ ^.,2000

421

Hiratsuka ^ d.,2000

GGT TTG-3'
P2M (Forward)

5'-GTA TGA TTT TAT GCA
GGT TTC-3'

P2C (Reverse)

5'-TAA AT A GGA ACC
ATC GGA CAG-3'

G460A

46F(Forward)

Transition

5'-ATA AC A GAG TGG
GGA GGC AGC-3'

46R(Reverse)

5'-CTA GAA CCC AGA
AAA AGT AT A G-3'

A719G

79F(Forward)

Transition

5'-CAG GCT TTA GCA TAA
TTT TCA ATT CCT C-3'
5'- TGT TGG GAT TAC

TPMT*4

79R (Reverse)

AGG TGT GAG CCA C-3'

*4F(Forward)

5'-AAC ATG TTA CTC TTT

Transition

CTT GCT-3'
*4R(Reverse)

5'-TCT CCT CTC CAA AGG
AGC TAC TTT-3'

TPMT *5

*5F (Forward)

Transition

5'-AGT A AC TGC TTA TTA
AGG TTG TTG G-3'

*5R(Reverse)

5'-TTA AGG AAA GTA TCT
AAA TGC TTC ATT-3'

TPMT*6

*6F (Forward)

Transversion

5'-CCA TCC TGG GAA
AGA AGT TTA CGT -3'

*6R(Reverse)

5'-TCC AAA CTG GAA TTA
TCT CCA TGT A-3'

TPMT*7

*7F(Forward)

5'-GGT TGA TGC TTT TGA
AGA ACT GCA-3'

Transversion
*7R (Reverse)

5'-CAG GTA AC A CAT
GCT GAT TGG-3'

TPMT*8

*8F(Forward)

Transition

5'-TTC TTG TTT CAG GTA
AAA TAT GCA ATA AAC-3

*8R(Reverse)

5'-CAG GTA ACA CAT
GCT GAT TGG-3'

* The G238C primers were fluorescently labelled (wild type G238C primer with 6-carboxyfluorescein
(FAM) and the mutant labelled with HEX (47,2'4,'5'7-Hexachloro-6-carboxyfluorescein).
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* The G238C primers were fluorescently labelled (wild type G238C primer with 6-carboxyfluorescein
(FAM) and the mutant labelled with HEX (47,2’4,5’7-Hexachloro-6-carboxyfluorescein).

2.1.2.6 Oligonucleotide ARMS Primers
Details of ARMS primers designed for the G460A and A79G TPMT mutation
detection and also used in the multiplex PCR reaction are shown table 2.4. Mismatch
bases are given in blue for clarity.

Table 2.4: ARMS primers used for G460A and A719G mutation detection.
Amplicon
Mutation
Primer
Sequence

Reference

Size (bp)
*G460A

46F (Forward)

5’-CAC ACT GTC CTT TGT

308

This study

454

This study

TCC TT-3’
46MWT (Reverse)

5’-GCA ACT AGT GCT CCT
CTA TC -3’

46MM (Reverse)

5’-GCA ATT AGT GCT CCT
CTA TC -3’

*A719G

719WT (Forward)

5’-GAC TGT CTT TTT GAA
AAG TTA TA -3’

719MM (Forward)

5’- GAC TGT CTT TTT GAA
AAG TTG TA-3’

719R (Reverse)

5’-GGT TGG GCA AC A
AGA ACG AA-3’

* The wild type and mutant primers were fluorescently labelled covalently at the
5’end G460A and A719 wild reverse primers primer with 6-carboxyfluorescein
(FAM) and theG460A and A719G mutant labelled with HEX (47,2’4,5’7Hexachloro-6-carboxyfluorescein.

2.1.2.7 Sterile Water
Distilled H2O (dH20) was sterilised by autoclaving at 121 °C for 15 minutes.
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2.1.3 PCR Product Purification
PCR amplicons were purified following amplification to remove possible interfering
substances using a QIAquick PCR purification kit prior to restriction analysis
(Qiagen).
This kit was supplied with QIA quick spin columns, 2 ml collection tubes, and buffers
designated buffer PB and buffer PE .

2.1.4 Restriction enzymes used in RFLP analysis
Various restriction enzymes were used to detect the presence of polymorphisms
within specific amplicons. The relevant enzymes and associated buffers were supplied
by New England Biolabs (New England Biolabs, Hertfordshire, UK) and are detailed
in Table 2.5.
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Table 2.5 Restriction enzymes, recognition sequences and associated buffers
Polymorphism
Recognition Sequence
Su/RE
Enzyme
Enzyme

Accl

A719G

Cut^M

activity

Buffer

(units/pl)

NE Buffer 4

10

NE Buffer

5

NE Buffer 3

20

NE Buffer 3

10

NE Buffer 4

3

5’GT at^aC...3’
Transition

CG
3’CA'^a TC
GC^

Mwol

G460A
Transition

.5.

1
5’GCNNNNNNNGC..3’
3 ’ CGNl^NNNNNCG.. 5 ’

Pstl

TPMT*7

5’..CTGCA^G..3’

Transversion
TPMT*4
Transition

Asel

3’.GACGTC..5’

t

TPMT*5
Transition

5’..TACGTA..3’
3’..TATTTA..5’

t

Acll

TPMT*8
Transition

5’..AACGTT..3’

and BSA

3’..ATGCAT..5’

f

SnaBl

TPMT*6
Transversion

NE Buffer 4
5’..TACGTA..3’
3’..ATGCAT..5’

t
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and BSA

5

2.1.5 Conventional Agarose gel Electrophoresis

2.1.5.1 Electrophoresis Apparatus
Two types were used
1) Horizon® 58 horizontal gel apparatus (for large gels)
2) Horizon® 11.14 horizontal gel apparatus (for small gels)
Both were obtained from Life Technologies Inc. (Rockville, U.S.A)

2.1.5.2 Agarose
Ultra Pure Agarose electrophoresis grade was obtained from Life Technologies Inc.
(Rockville,USA)

2.1.5.3 Ethidium Bromide
Ethidium Bromide (EtBr) was supplied by Sigma (Sigma, Poole, U.K). A working
solution of 10 mg/ml w
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2.1.5.5 Non-denaturing loading Buffer
The non denaturing loading dye was prepared as follows
6.6ml glycerol
3.3ml lOXTAE
10% (w/v) bromophenol blue

2.1.5.6 Molecular weight markers
Roche (Roche Diagnostics Ltd., East Sussex, U.K) supplied Grade V molecular
weight markers. These markers were generated by digesting pBR322 to completion
with restriction enzyme Hae III to yield 22 DNA fragments ranging in size from 8587 bp in length, (see Appendix 1)

2.1.6: Ultraviolet Transilluminator
Images were analysed and stored using the GRAB-IT™ software of UVPs Gel
Documentation and Analysis system GDS 8000 (Ultra-Violet Products Ltd.,
Cambridge, UK).

2.1.7: DNA sequencing analysis
A number of software programmes were used in this project to perform analysis of
sequenced amplicon and facilitate the design of allele-specific oligonucleotides.
Many of these programmes are freely available on the Internet and a review of those
used is shown below.
1. Tools to locate sequences in public databases by means of an accession number or
keyword searching.
GenBank® is the main public database used to locate sequences. GenBank® is
curated by the National Institutes of Health (NIH) at the National Center for
Biotechnology Information (NCBI) at the National Library of Medicine The
GenBank® database (www.ncbi.nlm.nih.gov/GenBank/) at the NCBI web is
updated daily and the ENTREZ search tool is used to retrieve sequences of
interest (http://www.nebi.nlm.nih.gov/ENTREZ).
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Once a particular GenBank sequence is located with ENTREZ it can be copied
and pasted into other sequence analysis programs, such as DNA sequencher™ for
further analysis. This tool was used to locate the TPMT gene (see Appendix 2 for
the TPMT gene sequence).

2. Tools for locating sequences in a database similar to a query sequence -similarity
searching. NCBI offers free BLAST searches of GenBank® over the Internet at
http://www.ncbi.nlm.gov/Blast/. This tool was used to confirm the primers
designed for the multiplex analysis were specific and would not amplify the
pseudogene.

3. Tools to aid in DNA sequencing process by assembling short overlapping
fragments into consensus sequences. Multiple DNA sequence alignments are
achievable using DNA Sequencer™ and Clustal W (Thompson et al., 1994). DNA
Sequencher™ from GeneCodes in Macintosh and Windows programme was used
for DNA sequence analysis.
Clustal W is the most widely available of the multiple alignment programmes
and is available over the Internet at the European Bioinformatics Institute,
Cambridge, England, UK at http.//www2.ebi.ac.uk/clustalw. It is an excellent
multiple alignement programme. Both of these tools were used to analyse the
DNA sequences achieved from the PCR amplicons and these were compared to
the TPMT gene to confirm the results obtained were correct.
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2.2 Experimental Methods

2.2.1 DNA extraction from whole blood samples
2.2.1.1 Preparation of buffv coat
Whole blood samples were centrifuged at 2000 rpm for 10 min. at room temperature
to achieve three fractions:
a) Plasma (the top layer)
b) Buffy coat (the thin intermediate layer)
c) Red cell concentrate (the bottom layer)
Supematent plasma was removed using a Pasteur pipette to allow easy access to the
buffy layer.

2.2.1.2 DNA extraction procedure
DNA was extracted from the leucocyte-rich buffy coat using the QIAamp blood kit
(Qiagen). Extraction involved the following steps as recommended by the
manufacturer:
•

20 pi of Qiagen protease and 200 pi of buffer AL were added to 200 pi of buffy
coat in a 1.5 ml eppendorf tube,. Thorough mixing was achieved by vortexing for
15 sec.

•

The mix was incubated for 10 min. at 70°C for complete lysis of leucocytes.

•

Subsequently, 210 pi of ethanol [96-100% (v/v)] was added and the lysate was
then placed into a QIAamp spin column positioned over a collection tube.

•

DNA was bound to the silica gel membrane of the spin column by centrifugation
at 8000 rpm for 1 min.

•

The spin column was washed twice with 500 pi of buffer AW (replacing the
collection tube each time) and finally the DNA was eluted with 200 pi of
preheated sterile dH20 (70°C) into a sterile 1.5 ml eppendorf tube.
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2.2.1.3 DNA Quantitation
The yield of purified DNA extracted was determined spectrophotometrically using a
UV-160A Shimadzu spectrophotometer by measuring the absorbance of the eluate at
260 nm and 280 nm in quartz cuvettes.
Purity of the DNA solution was determined by calculating the absorbance at 260nm
and 280 nm as a ratio (A260/280 ratio). Values of 1.7-1.9 indicated a pure preparation
devoid of contamination cellular protein.
Finally, electrophoresis of the DNA was performed to determine the integrity of the
DNA.
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2.2.2 PCR

Section 2.2.2.1 describes the amplification reaction conditions for the eight TPMT
mutations optimised from previously published work.

Section 2.2.2.2 shows the novel G460A and A719G ARMS assay conditions
developed in this study and also the conditions for the multiplex mutation screening
protocol designed in this project. The primers for these detection assays were
designed using suitable bioinformatic analysis (see Section 2.2.7)

2.2.2.1: PCR conditions for TPMT mutation screening

2.2.2. Ual G238C ARMS reaction
A DNA fragment (256 bp) was amplified with P2W and P2C primers when G238
(wild type) is present, whereas a DNA fragment (256bp)with P2M and P2C primers
when C238 (mutant) is present.
Contents of the two tube reaction used in the G238C ARMS PCR amplification are
shown in table 2.6 below.
Table 2.6: Amplification reaction conditions for G238C ARMS.
Component
Final Concentration Wild type
in PCR reaction
lOX Promega PCR Buffer

Mutant
PCR

5X

5 pi

5 pi

2.5mM

5 pi

5 pi

1 U

0.25 pi

0.25 pi

dNTPs

(1.25 mM)

8 pi

8 pi

P2W (forward primer)*

25 pmol/pl

1 pi

No addition

P2M (forward primer)*

25 pmol/pl

No addition

Ipl

P2C (reverse primer)*

25 pmol/fil

1 pi

Ipl

26.75 pi

26.75 pi

3 pi

3 pi

MgCb (25 mM)
Promega Taq Polymerase
(5 U/pl)

dH20
Genomie DNA template

(300 ng)

100 ng/pl
*Table 2.3 provides details of these oligonucleotide primers
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2.2.2. irbl G46QA PCR-RFLP PCR ASSAY
To detect the G460A transition mutation a PCR assay using primers P460F and
P460R (see table 2.3) was performed. A DNA product of 365 bp was amplified,
purified and digested using Mwo\. Digested products were analysed by conventional
agarose gel electrophoresis.
Mwo\ digestion of wild type DNA amplicons yielded fragments of 98 and 267 bp,
whereas DNA containing the G460A mutation was not digested.
The PCR reaction components required to detect the G460A mutation are shown
below in table 2.7.
Table 2.7 G460A PCR amplification reaction
Components
Concentration

Amplitaq DNA polymerase

Volume

5U/pl

0.2 pi

Genomic DNA template

(100 ng/pl)

3 pi

P460F forward primer *

(40 pmol/1)

0.1 pi

P460R reverse primer *

(40 pmol/pl)

0.1 pi

IX

10 pi

(1.25 mM)

8 pi

Buffer J Invitrogen
dNTPs
dH20

28.6 pi

*Table 2.3 shows the details of oligonucleotide primers P460F and P460R.

2.2.2.1[c1 A719G PCR-RFLP ASSAY
To detect the A719G mutation, a PCR assay using primers P719F and P719R (see
Table 2.3) was performed. The A719G mutation introduces an Accl restriction site
into the amplified fragment and yielded fragments of 86 and 207 base pairs. The wild
type DNA amplicon was not digested. The reaction mix for the A719G is shown in
Table 2.8.
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Table 2.8 Composition of A719G PCR reaction
Concentration
Components

Volume

Amplitaq DNA polymerase

(5 U/pl)

0.2 pi

Genomic DNA template

(100 ng/pl)

3 pi

P719F forward primer*

(40 pmol/1)

0.1 pi

P719R reverse primer *

(40 pmol/pl)

0.1 pi

Buffer N Invitrogen

IX

10 pi

dNTPs

(1.25 mM)

8 pi

dH20

29.6 pi

*Table 2.3 shows the details of oligonucleotide primers P719F and P719R.

2.2.2.1 rd1 Amplification rational for rare TPMT mutations (TPMT *4-*8)
Mismatch PCR-RFLP systems were developed by Hiratsuka et al., (2000) for
identifying the rare TPMT alleles. In each system one primer was designed to have
the specific sequence of the normal TPMT gene in order to avoid amplification of the
pseudogene. The other primer incorporates one or two mismatches which introduce a
restriction site for either the normal or the mutant allele.
All of the rare mutations were amplified using the same reaction conditions as shown
inTable 2.9 below.

TPMT *4: The forward primer (4F) was designed with 2-base mismatches and
introduce a Pst\ site except for the TPMT*4 allele. Amplified DNA was digested
with the restriction enzyme Pst\. The wild type allele only contains the Pstl site,
facilitating the RFLP analysis of the amplicon. Digestion of the 361 bp fragment at
the Pstl site produced DNA fragments of 22 and 339 bp.

TPMT*5: The reverse PCR primer (5R) was designed with a 1-bp mismatch and
introduced an Asel site except for the TPMT *5 allele. The wild type allele alone
contained an Asel restriction site, allowing RFLP analysis of the digested products.
Digestion of the 138 bp fragment yields smaller fragments of 28 and 110 bp.
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TPMT'^6\ A 230 bp DNA fragment was amplified using primers *6F and *6R. The
PCR product was digested with SnaBX.lht wild type allele alone contained the
restriction site allowing RFLP analysis of the digested products. Digestion of the 230
bp fragment yields fragments of 22 bp and 208 bp.

7PMr*7: The forward PCR primer (7F) was designed with a 2-bp mismatch and
introduced a PstX site. The mutant allele alone contained a PstX restriction site.
Digestion of the 378 bp fragment yields fragments of 24 and 354 bp.

TPMT*8: The forward primer (8F) was designed with 1-base pair mismatch and
introduces a AclX site except for the TPMT*8 allele. Digestion of the 421 bp fragment
yields fragments of 29 and 392 bp.

Table 2.9 Reaction mix for rare TPMT mutations

Concentration

Volume

3X

3 pi

MgCf

(2 mM)

2.4 pi

Promega DNA Taq

5 U/pl

0.2 pi

100 ng/pl

3 pi

* Forward primer

(20 pmol/pl)

1 pi

*Reverse primer

(20 pmol/pl)

1 pi

dNTPs

(20 pmol/pl)

4.8 pi

Component
Promega lOX Taq Buffer

Polymerase
Genomic DNA Template

dH20

14.6 pi

* Forward and reverse primers were incorporated as appropriate for mutation
detection see Table 2.3

All rare TPMT mutation PCR reactions were analysed by agarose gel electrophoresis
in 3% (w/v) agarose.
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2.2.2.2 Novel ARMS assays
The following PCR reactions were performed using primers designed in this project
see table 2.4.

2.2.2.2 ra1 G46QA ARMS ASSAY
Genomic DNA was amplified using the newly designed ARMS primers (see table
2.4). PCR products were then analysed by agarose gel electrophoresis. A DNA
fragment of 365 bp was amplified with the 46WT and 46F primers when G460 (wild
type) was present, whereas a DNA fragment was amplified with 46M and 46F primers
when 460G (mutant). Details of the two tube ARMS reactions are shown in table 2.10
below.

Component
Buffer J Invitrogen

Concentration

Wild type

Mutant PCR

IX

10 pi

10 pi

(5 U/pl)

0.2 pi

0.2 pi

46WT (forward primer)

40 pmol/pl

0.1 pi

-

46M (forward primer)

40 pmol/pl

-

0.1 pi

46F (reverse primer)

40 pmol/pl

0.1 pi

0.1 pi

5 pi

5 pi

5 pi

5 pi

29.6 pi

29.6 pi

Amplitaq DNA
Polymerase

dNTPs(1.25 mM)
Genomic DNA template

(100 ng/pl)

(100 ng/pl)
Sterile dH20
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2222 rb1 A719G ARMS PCR ASSAY
Genomic DNA was amplified using the newly designed primers (see table 2.4). PCR
products were then analysed by electrophoresis. A DNA fragment was amplified with
719WT and 719R primers when A719 (wild type) was present, whereas a DNA
fragment was amplified with 719M and 719R primers when 719G (mutant) was
present resulting in a PCR product of 454 bp.
The components of the A719G ARMS assay are detailed in table 2.11.

Component

Wild type

Mutant PCR

lOX Buffer N Invitrogen

10 pi

10 pi

AmpliTaq Polymerase (5 U/pl)

0.2 pi

0.2 pi

79WT (forward primer)

0.2 pi

40 pmol/pl
79M (forward primer)

0.2 pi

40 pmol/pl
79R (reverse primer)

0.2 pi

0.2 pi

dNTPs(1.25 mM)

5 pi

5 pi

Genomic DNA template

5 pi

5 pi

29.4 pi

29.4 pi

40 pmol/pl

(100 ng/pl)
Sterile dH20
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22.22 [cl Multiplex PCR design

The multiplex PCR allows the determination of the genotype of any individual using
the G238C ARMS assay and the newly designed G460A and A719G ARMS assays
simultaneously. Contents of reaetion tubes used in the PCR multiplex amplification
assay are shown in table 2.12 below.

Components

Tubel

Tube 2

Sigma lOX PCR buffer

10 pi

10 pi

dNTPs (2.5 mM)

8 pi

8 pi

P2M (25 pmol/pl)

1 pi

P2W (25 pmol/pl)

.

Ipl

P2C (25 pmol/pl)

1 pi

Igl

79 WT (40 pmol/pl)

1 pi

79 M (40 pmol/pl)
79 R

1 pi

(40 pmol/pl)

Ipl

46 WT (40 pmol/pl)

Ipl

46M

(40 pmol/pl)

46F

(40 pmol/pl)

Ipl

1 pi
1 pi

1 pi

Sigma Taq DNA Polymerase 5 U/pl

0.2 pi

0.2 pi

Genomic DNA template (100 ng/pl)

5 pi

5 pi

20.8 pi

20.8 pi

Sterile dH20
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22.2.3 PCR conditions used in the detection of TPMT mutations by traditional
molecular techniques.
Table 2.13 highlights the PCR protocols involved in the previously published G238
ARMS assay along with the G460A and A719G PCR-RFLP assays.
Table 2.13 PCR protocols
G238C
PCR
ARMS
Hot Start
None

G460A
PCR-RFLP
80°C for 1 min

A719G
PCR-RFLP
None

Initial
Denaturation

94°C for 5 min
(1 cycle)

94°C for 2 min
(1 cycle)

94°C for 5 min
(1 cycle)

Denaturation
Annealing
Extension
(cycles)

94°C for 1 min
55°C for 2 min
72°C for 1 min
(35 cycles)

94°C for 1 min
55°C for 2 min
72°C for 1 min
(35 cyeles)

94°C for 1 min
60°C for 2 min
72°C for 1 min
(35 cycles)

Final
Extension
(cycles)
Hold

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

4°C

4°C

4°C

2.2.2.4 PCR protocols used in the detection of rare TPMT mutations.
Below in table 2.14 the PCR protocols used to detect the rare TPMT mutations are
listed.
Table 2.14
TPMT*4

TPMT*5

TPMT*6

TPMT*7

TPMT*8

Initial
Denaturation

94°C for 5 min
(1 cycle)

94°C for 2 min
(1 cycle)

94°C for 5 min
(1 cycle)

94°C for 5 min
(1 cycle)

94°C for 2 min
(1 cycle)

Denaturation
Annealing
Extension
(cycles)

94°C for 1 min
49°C for 2 min
72°C for 1 min
(30 cycles)

94°C for 1 min
51°C for 2 min
72°C for 1 min
(30 cycles)

94°C for 1 min
59°C for 2 min
72°C for 1 min
(30 cycles)

94°C for 1 min
59°C for 2 min
72°C for 1 min
(33 cycles)

94°C for 1 min
61°Cfor 1 min
72°C for 1 min
(33 cycles)

Final Extension
(cycles)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

4°C

4°C

4°C

4°C

4°C

PCR

Hold
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2.2.2.5 PCR protocols involved in the novel PCR reactions.
Below in table 2.15 the PCR reaction conditions for the rare mutations indicated are
shown.
Table 2.15 describes the PCR protocols of the newly designed PCR reactions.
G460A ARMS
A719G ARMS
MULTIPLEX PCR
PCR
Hot Start

80°C for 1 min

80°C for 1 min

80°C for 1 min

Initial Denaturation

94°C for 5 min
(1 cycle)

94°C for 2 min
(1 cycle)

94°C for 5 min
(1 cycle)

Denaturation
Annealing
Extension
(cycles)

94°C
55°C
72°C
(35

94°C
55°C
72°C
(35

94°C
63°C
72°C
(35

Final Extension
(cycles)

72°C for 7 min
(1 eyele)

72°C for 7 min
(1 cycle)

72°C for 7 min
(1 cycle)

4°C

4°C

4°C

Hold

for 1 min
for 2 min
for 1 min
cycles)

for 1 min
for 2 min
for 1 min
eycles)

for 1 min
for 2 min
for 1 min
cycles)

All amplification reactions were performed using a PTC-150 minicycler (MJ
Research Inc., Watertown, MA). This thermal cycler possessed a heated lid that
obviated the need for a mineral oil layer to be placed over reaction mixes.
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2.2.3: Agarose gel electrophoresis
A 2% (w/v) agarose gel (Life Technologies., Rockville, USA) was used. Agarose was
solubilised in each case in IX TAE containing 10 mg/ml Ethidium Bromide (EtBr).
The PCR product was mixed with a non-denaturing loading dye and loaded on an
agarose gel. Electrophoresis was performed for 1-2 hours at 90 V. The blue non
denaturing loading dye facilitated visualisation on an ultraviolet transilluminator.
Images were analysed and stored using the GRAB-IT'^'^ software of UVPs Gel
Documentation and Analysis system GDS 8000 (Ultra-Violet Products Ltd.).

2.2.4: GeneScan Analysis
Fluorescent oligonucleotide primers for ARMS assay systems were synthesised and
purified by MWG Biotech . These were used in the PCR protocols as described in
Table 2.13 and 2.15. [F]- labelled PCR products were purified prior to GeneScan
analysis. The QIAamp purification kit (Qiagen Ltd.) was used for this purpose. An
ABI Prism™ 377 Genetic Analyser has the ability to accurately determine the size of
[F]-labelled DNA fragments and provided an alternative automated detection format
for the ARMS PCR products. This analysis was carried out by Oswel Scientific,
Hampshire, UK.

2.2.5: Sequencing of samples
As part of the PCR reaction validation process the DNA sequences of each amplicon,
was determined DNA sequence determined using dye-terminator chemistry protocols.
This sequencing confirmed the amplicon sizes and nature of the polymorphisms. All
sequencing was performed by MWG Biotech (Ebersberg, Germany) using the ABI
3700 sequencer and the ABI Big Dye Terminator Cycle Sequence kits.
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2.2.6: Restriction Endonuclease Digestion of Amplified Fragments
Following amplification the presence of mutations in amplified DNA fragments was
determined using Restriction Enzyme analysis. Restriction sites are created by the
presence of specific mutations and these determined the type of restriction enzyme
that was used.
The relevant enzymes used are detailed in Table 2.5. In general, the digestion protocol
used was as follows:

PCR Purification Product*

10.0 pi

Appropriate SuRE/Cut™ lOX buffer

2.5 pi

Restriction Enzyme

1.0 pi

Distilled H2O

11.5 pi

* A control digest was also prepared for each enzyme using 1 pi of A. DNA (0.25 pg).
The final volume was 50 pi. All tubes were incubated according to manufacturer’s
instructions and were usually analysed by electrophoresis in a 2% (w/v) agarose gel.
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2.2.7: ARMS Primer Design

2.2.7.1 Bioinformatics
The Internet
The following table outlines the web sites , known as URLs (Uniform Resource
Locaters), of database resources used in this study (Nierlich ^ d .,1999). Sequence
analysis of the existing databases, as a means of developing novel ARMS primers
required the investigation of all the URLs
URLs (Uniform Resource Locators)

Service/Database

http://wwv\'.ncbi.nlm.nih.gov/

GenBank is a database of all publicly available
nucleotide and protein sequences, including
supporting bibliographic and biological
information. Established in 1982 by the US
National Institutes of Health (NIH), has been at
the National Centre for Biotechnology
Information (NCBI) since 1992 a division of the
National Library of Medicine (NLM).
NCBI BLAST (Basic Local Alignment Search

http://www.ncbi.nlm.nih.gov/BLAST/

Tool) allows protein and DNA homology
searches.
NCBI Entrez allows retrieval of molecular

http://www.ncbi.nlm.nih.gov/Entez/

biology data and bibliographic citations from the
NCBI’s integrated databases.
NCBI PubMed is a bibliographic database

http ://www.ncbi .nlm.nih. gov/PubMed/

containing citations for nearly 9 million
biomedical articles from the National Library Of
Medicine’s MEDLINE and pre-MEDLINE
databases.
NCBI OMIM (On-Line Mendelian Inheritance of

http: //w ww, ncbi .nlm. nih. go v/OMIM/

Man) database is a comprehensive catalogue of
human genes and diseases.

22 1.2 DNA Sequencher™
.

Sequencher™ (Gene Codes Corporation, Ann Arbor, MI, USA) is a DNA sequencing
tool written for the Macintosh® family of desktop computers. The software was used
to analyse DNA and in the design of the ARMS primers. Integrated analysis features
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of Sequencher™ facilitated the identification of the Open Reading Frames and
ARMS primer design for the TPMT sequences.
2.2.7.3 Computational analysis of ARMS primers
•

The sequence of the relevant exon was located in GenBank using the NCBI
website (www.ncbi.nlm.nih.gov)

•

Within this exon, the sites of the PCR-RFLP primers were located.

•

Between the primer binding sites, the precise site of the mutation was identified

•

Two forms of the primer were then designated the 3’-nucleotide of one of the
forward primers being specific for the wild type allele and the 3’-nucleotide of the
other forward primer being specific for the mutant allele. In this case the reverse
primer functions as a common primer.

•

Due to the presence of a TPMT pseudogene on chromosome 18, was essential for
one pair of primers to have the specific sequence of the wild type TPMT gene
only.

•

The designed ARMS primers were then blasted into the GenBank DNA sequence
database to search for sequence similarities, and to authenticate the design of the
new primers.

•

Where necessary, mismatches were incorporated in the primers to avoid
amplification of the TPMT pseudogene.

•

The ARMS primers with mismatches were then blasted into the GenBank
database as a final check.
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Section 3
Results

3.0: Results and Discussion
Treating TPMT deficient patients with standard doses of mercaptopurine, thioguanine or
azathioprine can be fatal but such patients can be successfully treated without severe toxicity
if the dose is properly adjusted. Although TPMT deficiency can be diagnosed by measuring
TPMT activity in erythrocytes such measurements do not reflect constitutive activity in
patients who have received transfusions of red blood cells within two or three months of
testing. Due to the fact that transplant recipients or patients diagnosed with conditions such as
leukaemia occasionally receive allogenic transfusions of red cells it was necessary to develop
molecular genetic methods that are not affected by donor erythrocytes to improve the
therapeutic efficacy and guard against toxicity. These methods provide a more robust
detection assay with which to diagnose patients with TPMT deficiency or heterozygosity at
the TPMT gene locus. Due to the fact that genotype does not change it only needs to be
determined once,thus, these methods are clinically relevant and relatively inexpensive.

3.1: Extraction of Genomic DNA
Blood samples were collected from patients attending the Bon Secours Hospital in Cork. In
order to gain ethical approval for the study no access to clinical data was permitted. High
quality genomic DNA was purified from all 100 blood samples using the Qiagen DNA
extraction kit. The integrity of the template DNA was determined by conventional agarose gel
electrophoresis as can be seen by comparison with commercially prepared X DNA (Figure
3.1, lane 1).
DNA concentrations were determined by measuring the absorbance at 260nm. Finally the
DNA template concentration of all the samples was adjusted by dilution in sterile H2O to a
final concentration of 100 ng/pl.

Using in vitro molecular diagnostic techniques, the purified DNA was analysed to determine
the prevalence of a number of selected mutations implicated in TPMT deficiency using the
methods previously described (Yates et al., 1997). A novel multiplex ARMS assay was
designed which permitted rapid genotyping of the samples. The results of these molecular
analyses are shown and discussed in the following sections.
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Fi2ure 3.1: DNA extracted from test samples resolved in a 2% (w/v) agarose gel (used to
confirm the integrity of the 100 DNA samples by comparison with 500ng of commercial X
DNA).
Lane 1, X DNA; Lane 2, test sample 1 ; Lane 3, test sample 2 ; Lane 4, test sample 3 ; Lane 5,
test sample 4 ; Lane 6, test sample 5 ; Lane 7, test sample 6 ; Lane 8, test sample 7 ; Lane 9,
test sample 8 ; Lane 10, test sample 9 ; Lane 11, test sample 10 ; Lane 12, test sample 11 ;
Lane 13, test sample 12 ; Lane 14, test sample 13 ; Lane 15, test sample 14 ; Lane 16, test
sample 15 ; Lane 17, test sample 16 ; Lane 18, test sample 17 ; Lane 19, test sample 18 ; Lane
20, test sample 19.

3.2: Prevalence of G238C mutation
An ARMS assay amplification was used to determine whether the G238C transversion was
present at the TPMT locus (Yates et al., 1997).

In the G238C ARMS assay a DNA fragment of 256 bp was amplified using the P2M (mutant
primer) and P2C primer when C238 mutant was present whereas a DNA fragment (256 bp)
was amplified with P2W (wild type primer) and P2C when G238 wild type was present. The
principle of the ARMS assay is that nucleotides with a 3' base mismatch residue will not
function as an effective primer in a PCR reaction under appropriate conditions.
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For each sample, two reaction tubes are set up, the first with the P2W and P2C primer
combination and the second with P2C and P2M. Consequently, the two PCR reactions were
analysed in separate lanes of a 2% (w/v) agarose gel.

In Figure 3.2, the results of five wild type test samples are shown. In this figure, alternate
lanes contain the wild type and mutant primer analysis. It was determined that each of the
samples were of the wild type genotype (TPMT* 1/* 1) as the 256 bp PCR product was the
only DNA fragment detected in the first lane of each sample.

In Figure 3.3, a G238C heterozygote was detected (see lanes 1 and 2). A PCR product of
256 bp was detected in the two lanes for test sample 61, this genotype was denoted
TPMT*l/*2. The remaining lanes in this gel shows G238C analysis for samples 62-65 which
were determined to be of genotype TPMT* 1/* 1.

All remaining patients samples analysed for the G238C mutation were found to be
homozygous wild type with a genotype TPMT*1/*1. Of the 100 samples, only one patient
analysed was heterozygous for the G238C mutation with a genotype TPMT*l/*2. The
homozygous TPMT*2 mutation was not detected in any of the samples analysed.

The results obtained using this ARMS protocol permitted genotyping solely by inspection of
PCR products following agarose gel electrophoresis. This system is simple, reliable and does
not require further downstream analysis e.g. neither restriction enzyme digestion nor the
sequence analysis of PCR products. It clearly distinguishes heterozygotes and homozygotes.
The principle of the ARMS assay is based on the fact that nucleotides with a mismatch 3’
residue will not function as a primer in a PCR reaction under appropriate conditions.
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Figure 3.2: Lane M, grade V molecular weight marker; Lane 1, test sample 1 wild type
product 256 bp (primers P2W and P2C); Lane 2, test sample 1 no mutant product (primers
P2M and P2C); Lane 3, test sample 2 wild type product 256 bp: Lane 4, test sample 2 no
mutant product; Lane 5, test sample 3 wild type product 256 bp; Lane 6, test sample 3 no
mutant product; Lane 7, test sample 4 wild type product 256 bp; Lane 8, test sample 4 no
mutant product; Lane 9, test sample 5 wild type product 256 bp; Lane 10, test sample 5 no
mutant product.

Figure 3.3: Lane M, grade V molecular weight marker; Lane 1, test sample 61 wild type
product 256 bp (primers P2W and P2C); Lane 2, test sample 61 mutant product (primers P21V1
and P2C) product 256 bp heterozygous sample ; Lane 3, test sample 62 wild type product 256
bp: Lane 4, test sample 62 no mutant product; Lane 5, test sample 63 wild type product 256
bp; Lane 6, test sample 63 no mutant product; Lane 7, test sample 64 wild type product 256
bp; Lane 8, test sample 64 no mutant product; Lane 9, test sample 65 wild type product 256
bp; Lane 10, test sample 65 no mutant product.
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3.3: G460A Mutation Analysis
The analysis of nucleic acid composition is central in the determination of variation in DNA
sequence between individuals and underpins molecular genetics. Such analysis is routinely
performed by restriction fragment length polymorphism analysis. This approach has proved
enormously useful providing an extensive literature despite the fact that it is relatively slow
and only allows for the examination of the limited number of polymorphic base changes
which either create or destroy a restriction endonuclease recognition site.

Genotype TPMT*3A contains two point mutations G460-^A and A719^G, resulting in
Alal54-^Thr and Tyr240-^Cys amino acid substitutions respectively (Szumlanski et
al.,1996). The allelic variant that contains the G460->A polymorphism only is designated
TPMT *3B. When cDNAs containing either or both of these mutations were transiently
expressed in COS-1 cells, the presence of each mutation independently and together resulted
in decreases in expression of both TPMT enzymatic activity and immunoreactive protein
(Szunlanski et al.,1996).

To detect the G460A mutation, a PCR assay was optimised from the previous work of Yates
et al., (1997). An amplified PCR product of 365 bp was digested with the restriction
endonuclease Mwo\. Mwo\ digestion of wild type DNA yields fragments of 98 and 267 bp
whereas DNA containing the G460A mutation does not contain a recognition site for the
restriction endonuclease and consequently yields an uncleaved fragment of 365bp. The results
of these PCR and RFLP analysis were visualised after electrophoresis in 2% (w/v) agarose
gels.

All 100 samples analysed by this PCR-RFLP strategy were homozygous (i.e. wild type TPMT
* 1/* 1) The results of the G460A mutation analysis are shown in Figures 3.4 and 3.5. In
Figure 3.4, a PCR amplicon of 365 bp by comparison with grade V molecular weight markers
can be seen for each sample analysed. Figure 3.5 shows the corresponding Mwo\ digestion
results for sample 1-18. A known G460A PCR product was included in lane 1 for comparison.
(Note: faint bands were seen for sample 2 and the digest was repeated for sample 4 and this
sample was determined not to contain the G460A mutation).
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Figure 3.4: Electrophoretic analysis of G460A amplicon
Lane M, grade V molecular weight marker; Lane 1, test sample 1; Lane 2, test sample 2;
Lane 3, test sample 3; Lane 4, test sample 4; Lane 5, test sample 5; Lane 6, test sample 6;
Lane 7, test sample 7; Lane 8, test sample 8; Lane 9, test sample 9; Lane 10, test sample 10;
Lane 11, test sample 11; Lane 12, test sample 12; Lane 13, test sample 13; Lane 14, test
sample 14; Lane 15, test sample 15; Lane 16, test sample 16; Lane 17, test sample 17; Lane
18, test sample 18; Lane M, grade V molecular weight marker.

Figure 3.5: Results of Mwo\ restriction endonuclease digestion of G460A PCR amplification
products.
Lane M, grade V molecular weight marker; Lane 1, undigested PCR product 365bp; Lane 2,
test sample 1 following restriction enzyme digestion with Mwo I yielding fragments of 267
bp and 98bp; Lane 3, test sample 2; Lane 4, test sample 3; Lane 5,test sample 4; Lane 6, test
sample 5; Lane 7, test sample 6; Lane 8, test sample 7; Lane 9, test sample 8; Lane 10, test
sample 9; Lane 11, test sample 10; Lane 12, test sample 11; Lane 13, test sample 12; Lane 14,
test sample 13; Lane 15, test sample 14; Lane 16, test sample 15; Lane 17, test sample 16;
Lane 18, test sample 17; Lane 19, test sample 18.
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3.4: Prevalence of A719G mutation
Approximately 90-95% of the phenotypic TPMT deficiencies can be attributed to one of the
known mutations with approximately 75% of these known mutations attributable to the
TPMT *3 subtypes. The most frequent of these is the TPMT *3A variant allele, which can be
found in approximately 55% of deficient phenotypes and which incorporates two mutations.
The first single base mutation G460A located on exon 7, leads to an Ala-154-Thr amino acid
substitution, whereas the second mutation, A719G leads to a Thr-240-Cys amino acid
substitution this is found on exon 10. The TPMT *3B allele is defined by the presence of
G460A alone whereas TPMT *3C allele is defined by the A719G mutation alone (Schutz et
al., 2000).

Initially to detect the A719G mutation the PCR-RFLP assay of Yates et al., (1997) was used.
A PCR product of 293 bp is amplified. The A719G mutation introduces an Accl restriction
site in the amplified fragment and yields DNA fragments of 86 and 207 bp. Wild type DNA
remains uncleaved.
Figure 3.6 shows the A719G PCR product of 293 bp for samples 1-11. Figure 3.7
demonstrates the PCR products following restriction endonuclease digestion with Accl (for
another set of samples). All samples analysed with the exception of sample 45 (Figure 3.7,
lane 15) showed an uncleaved PCR product. Sample 45 produced three bands 293 bp
(uncleaved) and 86 and 207 bp (cleaved products) and therefore was determined to be
heterozygous for this A719G allele.

None of the 100 samples analysed were homozygous for the A719G mutation. Six samples
were heterozygous and subsequently denoted genotype TPMT*1/*3C. The remaining samples
were homozygous normal and therefore were wild type samples TPMT* 1/* 1.
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Fieure 3.6: A719G amplicon (293 bp) resolved in a 2 % agarose gel.
Lane M, grade V molecular weight marker; Lane 1, test sample 1; Lane 2, test sample 2;
Lane 3, test sample 3; Lane 4, test sample 4; Lane 5, test sample 5; Lane 6, test sample 6;
Lane 7, test sample 7; Lane 8, test sample 8; Lane 9, test sample 9; Lane 10, test sample 10;
Lane 11, test sample 11.

Figure 3.7: 2% agarose gel of Accl restriction digest analysis of A719G amplicon.
Lane M, grade V molecular weight marker; Lane 1, test sample 30; Lane 2, test sample 31;
Lane 3, test sample 32; Lane 4, test sample 33; Lane 5, test sample 34; Lane 6, test sample 35
Lane 7, test sample 36; Lane 8, test sample 37; Lane 9, test sample 38; Lane 10, test sample
39; Lane 11, test sample 40; Lane 12 , test sample 41; Lane 13, test sample 42; Lane 14, test
sample 43; Lane 15, test sample 44; Lane 16, test sample 45; Lane 17, test sample 46; Lane
18, test sample 47; Lane 19, test sample 48; Lane 20, test sample 49.
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3.5: Detection of Rare TPMT Mutations
Several mutations in the TPMT gene have been identified that correlate with decreased
activity of the corresponding enzyme. There are ten variant forms of the TPMT gene and
these are denoted as TPMT *2, *3A, *3C, *3B, *4, *5, *6 *7 and *8.

TPMT *2, *3A, *3C and *4 have been identified as being responsible for enzyme deficiency.
In contrast TPMT *5, *6 *1 and *8 are suspected to be associated with deficient TPMT
activity. There is a marked inter-ethnic difference in the frequencies of TPMT mutant alleles.
The most prevalent in the Caucasian population being TPMT *3A whereas TPMT *3C
predominates in the Chinese and Ghanian populations. (Kubota and Chiba, 2001). Other rare
mutant alleles have been recently identified in a single family of northern European ancestry
(TPMT *4) individuals of unknown ethnic origin (TPMT*5) a single Korean individual
(TPMT *6) a single European Caucasian (TPMT *7) and a single African American
individual (TPMT *8) (Kubota and Chiba, 2001).

The TPMT*4,*5,*6,*7 and *8 mutations are so rare, some having occurred in only one
individual that it was impractical to screen the test population for these specific mutations at
this time. However, PCR-RFLP assays for TPMT *4 -*8, previously described by Hiratsuka
et al., (2000) were optimised (data not shown). Where possible control material was obtained
to confirm validity of results obtained as part of this study. Figure 3.8 shows a composite gel
of the appropriate RFLP analysis of these amplicons.

In Figure 3.8, the expected TPMT*4 amplicon of 361 bp is seen in lane 1 for test sample 3.
Following restriction digestion with Pstl, two DNA fragments of 22 and 339 bp are seen
(Figure 3.8, lane 2). This assay confirms that the test sample does not contain the TPMT*4
mutant allele.
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A 138 bp TPMT*5 PCR amplicon is seen in figure 3.8, lane 3 for test sample number 5 as
expected. This product was digested with Asel and the result is shown in Figure 3.8 lane 4
where the 110 bp digested product is clearly visible. A control containing the TPMT*5 mutant
allele was included in the PCR-RFLP and as can be seen from lane 5, this product remained
undigested.

Similarly, Figure 3.8 shows the TPMT*6 amplification product of 230 bp for test sample 10
(lane 6). In Figure 3.8, the SnaBl digests of two test samples are shown in lanes 7 and 8.
Digested products of 27 and 208 bp confirm that these do not contain the TPMT*6 allele. A
control sample was included (Figure 3.8, lane 9), this remains undigested (230 bp).

PCR analysis for the TPMT*7 alleles (sample 12) amplified a product of 378 bp (Figure 3.8,
lane 10). The mutant alone contained the Pstl recognition site and in this case the test sample
remains undigested (Figure 3.8, lane 11).

In figure 3.8, a 421 bp TPMT*8 amplicon was amplified test sample 15 (lane 12). Digestion
of this product with the restriction enzyme Ac/1 produced DNA fragments of 29 and 392 bp
(lane 13). In this RFLP analysis, the wild type contained the Ac/1 recognition site.
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Figure 3,8: A composite gel showing restriction polymorphism analysis used to detect rare
TPMT mutations. A 2% (w/v) agarose gel stained with ethidium bromide was used
Lane M, grade V molecular weight marker;
Lane 1, TPMTM test sample 3 undigested PCR product 361 bp; Lane 2, TPMT*4
homozygous wild type test sample 3 following digestion with Pst I yielding fragments 339 bp
and 22 bp;
Lane 3, TPMT*5 undigested PCR product 138 bp; Lane 4, test sample 5 digested with the
restriction endonuclease Ase I yielding digested product of 28 and 110 bp; Lane 5 control
sample with TPMT*5 allele, the mutant does not contain a recognition site for the restriction
endonuclease and consequently is undigested (this lane contained a control template
previously cloned into pCR 2.1. the latter vector was detected in lane 5 as the upper DNA
fragment which did not contain an Ase\ site);
Lane 6, TPMT*6 undigested PCR product at 230 bp; Lane 7, test sample 10 contains the
recognition site for SnaB I and is therefore digested yielding products 27 and 208 bp; Lane 8,
test sample 11 yields digestion products of 27 and 208 bp; Lane 9, TPMT*6 control sample
this sample does not contain a recognition site and consequently is undigested (230 bp)
Lane 10, TPMT*7 undigested PCR product at 378 bp; Lane 11, test sample 12 the mutant and
not the wild type allele contains the recognition site for the restriction enzyme and therefore
following digestion with Pst I the sample remains undigested at 378 bp.
Lane 12, TPMT*8 undigested PCR product at 421 bp; Lane 13, test sample 15 the wild type
contains the recognition site fox Acl I and is therefore digested yielding products of 29 and
392 base pairs.
(Note; + = digested with the corresponding enzyme and - + undigested)
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In summary at this point the results obtained in the above sections involved a combination of
experiments. The test population of 100 samples were screened using an ARMS assay format
for the G238C mutation. One of the samples was found to be heterozygous for the mutation
and was denoted by the genotype TPMT*l/*2. All other samples were TPMT* 1/* 1 wild type
samples.
The G460A and A719G mutations were analysed by PCR-RFLP assays. All 100 samples
analysed for the G460A mutation were wild type TPMT* 1/* 1. However six samples of the
test population were heterozygous for the A719G mutation (TPMT*1/*3C) the remaining 94
samples were wild type TPMT*1/*1.

The overall objective of this study was to develop an automated TPMT genotyping protocol..
An ARMS based assay would allow the determination of the TPMT genotype without the
necessity for post-amplification conformation, thereby reducing the time required to detect the
mutations.

The optimised PCR-RFLP based method although a sensitive and efficient method for
genotyping of the TPMT mutations. It is however time consuming and laborious. By their
nature PCR-RFLP methods require post amplification digestion with a unique restriction
endonuclease (and in some cases rare) which maybe expensive and consequently this method
would not be practical for routine screening. Also the agarose gels, following digestion may
be at times difficult to interpret, and, therefore an alternative detection strategy would be
beneficial. The PCR-RFLP based methods were time consuming, as each mutation must be
investigated separately this consequently results in additional resources being required. A
simultaneous detection system would therefore be a more benefical and cost effective strategy
to screen template DNA for these important mutations.

Although multiplexing requires careful primer design and optimisation experiments it is
highly efficient and cost effective strategy for genotyping .
A multiplex test assay based on the ARMS format was developed to simultaneously detect the
G460A and A719G alleles. The experimental design and optimisation format and its
subsequent conversion to a fluorescence based system is described in the following section.
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3.6: Design of allele specific primers; towards the development of a modified [F] ARMS
format
In order to develop a multiplex ARMS assay, allele specific primers were redesigned. TPMT
has a complex molecular structure. The presence of the known pseudogene may often
complicate molecular assays, possibly leading to false positives and in this study the
following strategy was adopted which consisted of the redesign of primers for G460A and
A719G

The target mutation site that was first developed for this assay was identified. Size of resulting
amplicons was an important consideration since DNA fragments were required to be
sufficiently spaced upon agarose gel electrophoresis to permit detection. A wild type primer
and a mutant primer pair was designed to enable the detection of G460A and A719G alleles in
a single tube reaction.

To pro^ide additional conformation the newly designed primers were analysed against the
current database using the BLAST search tool (www.ncbi.nlm.nih.gov/BLAST). This step
ensures that primers designed were specific and selective for the target gene and that they do
not co-amplify the resident pseudogene.

The primer sets were tested individually in the G460A and A719G ARMS assays prior to the
optimisation of the multiplex DNA detection system.
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3.7; Development of a novel G460A ARMS assay
Once the G460A primers were designed, optimisation of the PCR conditions followed. The
G460A ARMS assay consists of an experiment wherein tube 1 contains the wild type primer,
tube 2 contains the mutant primer with a common forward primer in both. Once, the method
was optimised the test population was screened for the G460A mutation. An amplicon of 356
bp was detected following agarose gel electrophoresis.
Figure 3.9 shows the G460A ARMS assay results for nine of the test samples. It can be seen
from these results that none of the samples contained the G460A mutation, as only the lanes
with wild-type ARMS primers showed amplification products.

Similarly none of the 100 study samples analysed possessed the G460A mutation and these
results corresponded with those previously obtained using the PCR-RFLP-based methods
outlined in Section 3.3 of results and discussion. This method obviates the need for the use of
a restriction enzyme {Mwo\ which is an expensive consumable item). In contrast to previous
methods (Yates et al., 1997) this new assay format was sensitive, efficient and more cost
effective for screening of TPMT- related mutations.
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Figure 3.9: Results of the novel G460A ARMS assay analysed by 2% (w/v) agarose gel
electrophoresis. In this gel, there are two lanes for each sample tested, the first containing the
wild type primer (Wt) and the second containing the mutant primer (M).
Lane M, grade V molecular weight marker;
Lane 1, wild type test sample 11; Lane 2, wild type test sample 11; Lane 3 test sample
12;Lane 4 test sample 12; Lane 5 test sample 13;Lane 6 test sample 13; Lane 7 test sample
14;Lane 8 test sample 14; Lane 9 test sample 15;Lane 10 test sample 15; Lane 11 test sample
16;Lane 12 test sample 16; Lane 13 test sample 17;Lane 14 test sample 17; Lane 15 test
sample 18;Lane 16 test sample 18; Lane 17 test sample 19;Lane 18 test sample 19.

Figure 3.10: 2% agarose gel showing the A719G ARMS assay results for the 5 test samples.
Alternate lanes in the gel contain the wild type and mutant primer amplification products for
each sample. In this gel, there are two lanes for each sample tested, the first containing the
wild type primer (Wt) and the second containing the mutant primer (M).
Lane M, grade V molecular weight marker

Lane M, grade V molecular weight marker;
Lane 1, wild type test sample 20; Lane 2, wild type test sample 20; Lane 3 test sample 21
TPMT*1/*1 product amplified in tube 1 454bp;Lane 4 test sample 21; Lane 5 test sample 22;
Lane 6 test sample 22; Lane 7 test sample 23; Lane 8 test sample 23; Lane 9 test sample 24;
Lane 10 test sample 24.
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3.8: Development of an A719G ARMS detection assay
This newly developed A719G ARMS assay is a two tube reaction similar to the ARMS assay
developed for the G460A mutation however in the case both tubes contain a common reverse
primer, tube 1 contains the wild type primer and tube 2 contains the mutant primer. Having
developed the oligonucleotide specific primers and having determined that these primers were
specific for the TPMT gene the ARMS assay was optimised. The expected amplicon was 454
bp and the results were easily visualised by agarose gel electrophoresis. This detection system
was then used to screen the sample population for the A719G mutation.

A selection of the sample population A719G ARMS results are demonstrated in Figure 3.10.
Of the five samples shown, four did not contain the A719G mutation as no fragment was
amplified in tube 2 of the ARMS system. However, for sample 22, a band was evident in both
tubes (see lanes 5 and 6) and therefore it can be concluded that this sample is heterozygous for
the A719G mutation.
None of the samples analysed were homozygous for the A719G mutation. Six samples were
heterozygous for the A719G mutation. The remainder of the one hundred studied samples
analysed were homozygous normal. These results corresponded with the results previously
achieved by PCR-RFLP based method as described in Section 3.4 of the results and
discussion.

Compared with the later method this format is faster, less expensive and does not require
endonuclease digestion. In addition this format may therefore offer a more practical routine
screening strategy for the A719G mutation.
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3.9: Development of a Multiplex Genotyping Assay for TPMT mutation detection
Due to the fact that TPMT*2 and TPMT*3 subtypes account for over 96% of the mutations
occurring in the Caucasian population these mutations would be the most clinically relevant in
a Caucasian population and consequently a strategy to simultaneously detect these mutations
would be useful.

To this end, a novel multiplex ARMS assay was designed. The assay format utilises the
previously published ARMS assay for the detection of the G238C mutation (Yates et al.,1997)
and combines this strategy with the newly developed G460A and A719G ARMS detection
systems thus providing a simultaneous detection format for the detection of the three most
prevalent mutations in the Caucasian population.

This method is less time consuming as all three PCR assays can be simultaneously carried out
in a two-tube reaction. The detection strategy, once optimised does not require post
amplification modification and consequently is less expensive and less laborious than the
previous methods.
The detection system involves a two tube reaction with tube 1 containing the allele specific
primers for A719 wild type, G460 wild type and G238 mutant and tube 2 containing the
primers for 719G mutant, 460A mutant and G238 wild type. With this configuration products
are obtained in both tubes as there is a wild -type primer in each which acts as an internal
control for the PCR assay itself Figure 3.11 shows a schematic representation of the
mechanics of the two tube assay. Using the multiplex ARMS system, a test sample that does
not contain any of the three most prevalent point mutations should on an agarose gel produce
only two DNA fragments of 356 and 454 bp in the first reaction tube and a single band of 256
bp in lane 2. Extensive optimisation experiments were conducted to validate the results. Once
completed these optimisation protocols provide a more simple screening strategy to detect the
three most prevalent TPMT mutations in a Caucasian. Figure 3.12 and 3.13 illustrate some of
the test results.
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Figure 3.11: Schematic review of the [F] labelled ARMS assay.
A ARMS amplicon sizes
AUele

G238C

G460A

A719G

Size (bp)

256

356

454

B Fluorescent GeneScan results for a homozygous normal individual
Corresponding Primers

Tube 1: Top Panel
238C
G460
A719
Tube 2; Bottom Panel
G238
460A
719G

C Fluorescent GeneScan results for a G238C heteroozygous individual
Corresponding Primers

Tube 1: Top Panel
238C
G460
A719
Tube 2: Bottom Panel
G238
460A
719G

A: Table showing the expected amplicon sizes from the TPMTmultiplex assay.
B: Results of the two tube multiplex PCR for a normal individual analysed using GeneScan technology.
The red peaks in the panels represent the internal lane standard and the blue peaks indicate the normal
alleles detected. The table on the right of the GeneScan shows the primers corresponding to each tube
of the multiplex assay.
C: Expected GeneScan results for a patient sample heterozygous for the G238C allele. Red peaks represent
the internal lane standard and blue peaks are present for the normal alleles. Where a point mutation is
detected a black peak is observed.
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Figure 3.12: Multiplex ARMS assay results resolved in a 2% agarose gel.
Lane M, grade V molecular weight marker;
Lane 1 and 2, test sample 1; Lane 3 and 4 test sample 2; Lane 5 and 6 test sample 3; Lane 7

and 8 test sample 4; Lane 9 and 10 test sample 5; Lane 11 and 12 test sample 6; Lane 13 and
14 test sample 7; Lane 15 and 16 test sample 8; Lane 17 and 18 test
sample 9.

Figure 3.13: 2% agarose gel showing results of a multiplex ARMS system.
Lane M, grade V molecular weight marker;
Lane 1 and 2, test sample 10; lane 3 and 4 test sample 45; lane 5 and 6, test sample 61.
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In summary the multiplex ARMS assay data correlated exactly with the results obtained using
conventional molecular approaches for the detection of the common TPMT genotypes among
the Caucasian population i.e. G238C ARMS, G460A and A719G PCR-RFLP. In addition,
when the newly designed G460A and A719G assays were used individually to detect the
appropriate point mutations, these systems provided identical genotyping.

Of the 100 samples analysed for the three point mutations, 93 did not contain any of the thret
most prevalent TPMT mutations. Therefore it was concluded that the genotype of these
individuals was TPMT*1/*1.

The remaining samples were determined to have at least one of the three point mutations.
These results are summarised in table 3.1 where + represents a point mutation in one allele.
Table 3.1 Summary of the samples determined to have at least one point mutation
Test sample
G238C*
G460A*
A719G*
Genotype
number
61

-/+

-/-

-/-

TPMT*l/*2

22

-/-

-/-

-/+

TPMT*1/*3C

16

-/-

-/-

-/+

TPMT*1/*3C

33

-/-

-/-

-/+

TPMT*1/*3C

45

-/-

-/-

-/+

TPMT*1/*3C

55

-/-

-/-

-/+

TPMT*1/*3C

96

-/-

-/-

-/+

TPMT*1/*3C

*G238C mutation detected by G238C ARMS and multiplex analysis.
'^G460A mutation detected by G460A PCR-RFLP, G460A ARMS and multiplex analysis.
^A719G mutation detected by G460A PCR-RFLP, G460A ARMS and multiplex analysis.

In addition a bar chart (see figure 3.14) provides a graphical representation of the prevalence
of the G238C, G460A and A719G point mutations in the sample populations in the study.
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Figure 3.14: Prevalence of the three most

common point TPMT genotypes in an Irish
sample population
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3.10: GeneScan Analysis-adaptation to fluorescent based detection
The development of GeneScan technology has provided an automated system which can
accurately size and quantitate DNA fragments. The system is flexible and permits the
labelling of DNA fragments with up to three differentially coloured fluorescent dyes with a
fourth dye used for labelling of the internal size standard.

The allele specific oligonucleotides developed in the multiplex ARMS assays previously,
were fluorescently labelled. The fluorescent tags did not interfere with amplification
efficiency however inclusion of fluorescent labels on PCR products during amplification
decreases the electrophoretic mobility of the resultant amplicons. Therefore a small increase
was observed in the size estimations of [F] labelled DNA fragment using GeneScan analysis
(data not shown).

Inclusion of fluorescent labels on the oligonucleotide primers facilitated the detection of [F]
labelled PCR products using GeneScan technology. The wild type primers were labelled with
6-FAM (blue) and HEX (black) was used to label the mutant primers developed previously.
As the Gene Scan analysis was performed off-site (Oswel Hamshire UK), a limited selection
of samples were analysed see figure 3.15, 3.16 and 3.17. In this analysis a TAMRA (red)
2500 internal standard was included.

In figure 3.15 the GeneScan data for a normal individual (test sample number 2) is shown.
The top panel of the figure corresponds with tube 1 of the ARMS assay and the bottom panel
with tube 2 see section see section 3.9 results and discussion. Three blue peaks are visible and
could be sized by comparison w'ch internal size standard, the sizes of the fluorescent products
can be estimated as shown in Figure 3.15. The wild type primers were labelled with 6-FAM
(blue) sample number 2 yielding three normal alleles following PCR.

In figure 3.16 shows the GeneScan results for sample 22. In this figure, the top panel has two
blue peaks at 356 and 454 bp while the bottom panel has a single blue peak at 256 bp and a
black peak at 454 bp. This indicated that a mutation at the A719G gene locus consistent with
a TPMT *1/*3C genotype.
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In figure 3.17, a heterozygous individual for the G238C mutation was detected by GeneScan.
In the top panel three peaks are present the two blue peaks representing the wild type alleles
of A719G and G460A and a black peak representing the mutant form of G238C. In the
bottom panel a single peak is present representing the normal G238C allele. These data
confirm that this sample (test sample number 61) was heterozygous at the G238C locus
consistent with the TPMT*l/*2 genotype.

This data suggests that a sensitive and specific automated detection system of detecting the
three most prevalent mutations in the Caucasian population was developed. Fluorescent
labelling of primers used in the multiplex assay followed by this GeneScan analysis produced
a final result that was visually simple to interpret. GeneScan detection of fluorescent
amplicons in this manner provides a sensitive, “walk-away” automated format capable of
high-sample throughput and automatic data interpretation of results (Cotter et al., 1998)
consistent with the requirements for assay design in a clinical setting.
In summary these findings suggest that a sensitive and highly specific automated detection
system can be applied for routine screening for the TPMT mutations.
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Figure 3.15:

GeneScan results of the multiplex TPMT assay applied to test sample number 2.
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Figure 3.16: Fluorescent analysis of test sample 22.
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Figure 3.17: GeneScan analysis of test sample number 61,
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Section 4
Conclusions and Future Directions

4.1: Conclusions and Future Directions
1. A detailed knowledge of pharmacogenomics to individualise drug therapy offers the
potential to improve drug therapy, reduce adverse side effects and provide cost effective
therapeutic care. Although TPMT deficiency can be diagnosed by measuring TPMT
activity in erythrocytes, such measurements do not reflect constitutive activity should the
patient concerned have received transfusions of RBCs within the past two or three
months. Molecular methods are sensitive to these constraints and therefore have the
potential to provide a robust approach to detect mutations directly at the TPMT gene
locus.

2. In this study a sensitive, specific multiplex TPMT mutation detection strategy was
developed. Two formats were developed one using conventional agarose gel
electrophoresis and the second making use of advances in GeneScan technology for
detection of the mutations. Both provided data that was easy to interpret, results showed
that both of these methods correlated with the conventional molecular approaches used for
detection of the three most prevalent mutations. However, in our case these methods
provide simultaneous detection of G238C, G460A and A719G which is a faster and more
cost effective strategy.

3. Of the 100 samples analysed, only 7 were defined as heterozygous for one of the common
mutations. None were homozygous for the mutations detected. The frequency of the
heterozygous genotype is less than expected (a usual frequency of 1 in 10 is often
reported). It is not surprising that no samples were homozygous for the common
mutations (usual frequency 1 in 300), the sample population would have to be larger to
increase the possibility of detection of homozygote genotypes.

4. It is worth noting that the most common mutation was TPMT* 1/*3C. It would be
expected that in Caucasian population the TPMT*3 A genotype (containing both G460A
and A719G point mutations) would be more prevalent. As clinical data for these patients
was unavailable for ethical reasons, it could not be determined if the sample population
was a homogeneous Caucasian population. It may be that demographic changes in our
Irish population (with increasing numbers of individuals from different ethnic origins) are
now being reflected in our hospital population, resulting in a shift towards the *3C
genotype which is more common in Chinese and Ghanian populations. Increasing the
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sample population size and acquiring access to clinical data may help to further explain
this observation.

5. In this work, PCR-RFLP assays for the TPMT rare mutant alleles *4,*5,*6,*7 and *8
were optimised from previously published work (Krynetski et al., 2000). It is extremely
unlikely that these mutations would present a problem in an Irish clinical setting, at this
time. However, in time due to increasing medical investigations and legal implications it
may be essential that screening for all TPMT mutations be performed to provide definitive
genotyping for an individual. To this end preliminary work in our laboratory has
investigated the possibility of expanding the multiplex assay to incorporate the rare
alleles. To date the development of allele specific oligonucleotides for TPMT*7 and *8
has been successful. Due to substantial sequence homology to the TPMT pseudogene
design of allele specific oligonucleotides for*4,*5 and*6 proved to be more problematic.

6. Molecular biology is increasingly finding niches in the clinical laboratory. Roche
Diagnostics has developed a fluorescent probe hybridisation kit for TPMT mutation
detection for use with the Light Cycler Analyser. Light Cyclers are not available in routine
laboratory settings and this limits the application of these kits. Furthermore, given the
choice the basic techniques such as PCR and agarose gel electrophoresis are no longer
viewed as specialist research tools. Laboratories performing TPMT genotyping are
currently using the individual DNA based systems. The development of this multiplex
approach which does not require post-amplification analysis represents a more flexible
and accessible TPMT genotyping assay.
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Appendix 1

26/
234
213
192
184
124/123
104
89/80
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21/18/11/8

DNA Molecular weight marker V . All Molecular weight

markers were supplied by Roche Diagnostics, East Sussex,
UK.
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DNA
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PRI 22-AUG-2000
Homo sapiens TPMT gene for thiopurine S-methyltransferase, complete
cds.
AB045146
ABQ45146.1 GI:8777468
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Published Only in DataBase (2000)
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tcttttaagt

Details

cgctgaagag
taggggggtt
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gggcaggagg
cacaggggga
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cagcgaggcg
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gccgcttccg
gggtagggtc
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tttccccagc
tgatccctgg
ttacacaggt
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tttgaaaagg
attgtgaaat
aactttattt
cagctaagac
ctctacaaaa
tcaggaggtt
caccactgca
gacatgatta
gagttgtgct
agagaactgc

gtgccgggag
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aattccccct
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tgatgtggga
gtatgtatat
agtttcttct
tgagaatgga
ttcccttcct
ctctagaaat
gttgagccca
tatttaaaaa
gaagtgagag
ctccagcctg
agttatgtgc
actccaggct
tttatgaagc
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cgggaactga
ggaggcgggg
tacccgcccc
aggtaggctc
tatgcgcccg
cctgtgaagt
tgacctgaat
tttttttttc
gtggcacaat
cagcctcctc
ttttttttta
gggaaaaaat
ctgtaaatat
caccgagtca
aaatttaaaa
acttgaggac
aatgtgcact
agtggagtcc
accagcctgg
atggtggtgc
gccccagtgt
agagaccctg
tagacagttc
tctgataaag
ggttccagag
caatataaat
catcagggtc
cccaggtaat
caacaaaagg
attaatcatt
ctaatgattt
tgacattgaa
tcagctgaag
cagactgtag
aactgacact
atatacatat
ccatgagtaa
caggatggag
actgtgcatt
acaaaaggag
gctggtttcc
atagagttgt
ctggggtccc
cctgggcaac
agaaagtgtg
atgtcttttt
tatttgaaaa
ctttaatctg
ctaggatagc
gtgggaaagg
attgagcagc
acctccataa
gaacaggcca
ccacaccagc
tagactgaga
attgaataca
gtatatgaca
ggaaagtctg
gcagtcccag
ctgtattgtg
aaataaataa
ccactcacat
cctattcttt
tgcagtggca

tccggagccg
tctcggccgc
gagccgacag
ccgccctgcc
gtgcaacgag
ggcggggcgc
cgcgggcgga
tggggacgtc
actcgggcgc
tgctagggct
ggggttcagg
ccaatgtcca
ttttttcttt
catagctcac
agtaactggg
tagaaacgga
aagtactgcc
tctgtcttgc
tactctttta
acaaaactat
tttgtttgtg
ttttttgtat
atgctgagaa
gtaacatagc
acccttatag
tggagacgga
tctcaaaaac
aagtttgtgt
attatgcttc
tttctgaatg
cagatacttt
ttgcagaagc
gagagaaatg
ggaaatt tgc
aaattagaac
aaagggaatg
aggaaaggca
aatgagaagt
agcagccatt
tccagggagg
tcagttagct
ttgagcttca
tttttggccc
ctcagtagac
gggcagcatc
cttaagccct
atctgacgct
gttagccaag
aagagcgaaa
ccttcagtca
tcagtttcct
tacaaatgtg
tttttgctgt
caggacagga
attttgcaac
ccagtttgca
agtgtgagag
aatccccaga
aggctttggg
agatatgata
gcaaactgga
gtggctccaa
actaccacaa
atactttaaa
ccactgcact
ataaataaat
caccctacat
tttttgtttt
ccatcatagc

cgcgccgcgc
cgccgccgcc
gactagggat
catttccgcc
gtacggggcg
gggaaagagg
ggcggggcgc
attggtggcg
ggagggtgcg
cccaggaatt
gcagaagcgg
ggatttaaag
tagagacagg
tgtaacctgg
actacaggct
ctctcggttt
aaatagtgag
tctgcggtgg
agatgtgtgc
agcagaagct
ggcagaaatt
tatagaaata
actgttagaa
aagaccctgt
tcccaggtac
agtgtcatta
aaacaactaa
gaaaggaata
tcttttaagt
aaaatgagaa
ctactgacct
catttgtcaa
cctcctccct
ctgaaataca
caccaataat
ttagaataat
ttttcctcat
tcataattta
ctgactggct
ggcaaaggga
gtaggatgac
tgggtaccat
tcttatatca
tggccagaac
agggggttgg
tatagaacaa
ctatctactc
aaagtgtgta
ctccatctca
gttgagaggc
tagtgtgcat
tggagtagag
ctcctgaaaa
gagacaaaat
ttcaaggaag
atacagaatc
tatggttgaa
tccttttctc
gatttattct
cacagttgag
tgctgggacc
cgacagaatc
ggaaattaaa
ggctgaggcg
acagcctggg
aaataaataa
tataagcccc
tttcttaaga
tcactgcagc

gcacaggacg
gccgcttccg
gggtagggtc
gctgcgcaaa
ggagtggaga
cggggcgcgg
ggagaagtgg
gaggcaatgg
ggtgagaaag
cttacaagcg
aaactgggaa
tgcttccaaa
gtctccctct
aactcctggg
cgctgcacca
tttccccagc
tgatccctgg
ttacacaggt
accttaggaa
tttgaaaagg
attgtgaaat
aactttattt
cagctaagac
ctctacaaaa
tcaggaggtt
caccactgca
gacatgatta
gagttgtgct
agagaactgc
aactgcaaca
ctcagaaaac
caaatatttg
atatcctaag
tgcttttatg
agcatgctag
ggtgttatat
acattcagat
gaaaggagaa
gagaagtgta
acaggaattt
tcatgaatat
gcacaaaaaa
aaaggtgaag
cattctgtgg
ttgatatcag
agcctaattg
ttggcccaga
gtgagccaag
aaaaaaaaaa
tttgaatttt
ttcccatgca
ataggatatt
taacagaatt
tagtaaaatt
ctgaattcta
cccaaatgct
acaaggagga
aacttcttgc
ctggaaaggg
catgggagta
ctcgcccact
cttaagacag
gacattagcc
ggaggatcac
tgacagagcg
ataaatcaat
acccatatct
caaggtcttg
ctcgaactcc

http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

gctgcagccg
cccctgtcac
cccgccttcg
ccccggcgct
cggggcgccg
gaaagaggcg
cggaggtgga
ccggcaacca
ggaacgattt
tagacagcct
taacgaggtc
gcactggtgt
gtcgcccatg
ctcaagtgat
cgcttggcta
ctggtgtatt
tgatgtggga
gtatgtatat
agtttcttct
tgagaatgga
ttcccttcct
ctctagaaat
gttgagccca
tatttaaaaa
gaagtgagag
ctccagcctg
agttatgtgc
actccaggct
tttatgaagc
ttcttttgct
tcagagtcac
ctaagaagtg
catactgagg
caatgtttgc
tataatccaa
tgtccttaat
ggatctgcag
ctctttctca
gccgcaggcc
atgctgagga
ttatgaaagg
tggcggtgtt
cagaggacag
tctgtgatct
tggtagaatc
tggttagcaa
actcagtttt
atcgcaccac
aaagaaagaa
attgttagtt
aaaaagaagc
gaactatggt
tttttttaag
ttggaaaggc
aaccagcaat
caggattagc
ttgcttgaaa
aaccaagtgt
taaaacaaag
tacaggaaac
tctcttcttt
gaattgggag
aggcatgagg
ttgagcccag
agaccctgcc
ctaggttttc
ttgccttcat
atctgtagcc
taggctcaag

4561
4621
4681
4741
4801
4861
4921
4981
5041
5101
5161
5221
5281
5341
5401
5461
5521
5581
5641
5701
5761
5821
5881
5941
6001
6061
6121
6181
6241
6301
6361
6421
6481
6541
6601
6661
6721
6781
6841
6901
6961
7021
7081
7141
7201
7261
7321
7381
7441
7501
7561
7621
7681
7741
7801
7861
7921
7981
8041
8101
8161
8221
8281
8341
8401
8461
8521
8581
8641

ccatcctcct
gccaatttta
aaactccagg
gcaaaaaaaa
agaaaatagt
accgggtcag
cagagggatg
gctggtgaat
atctctatta
actcaggagg
tggcccccac
gaatagtcta
ctctttcagg
acaacaaaaa
ccagaatgat
tcagggcaga
gagagactga
aggagtaagt
tttggagagc
gtatattctt
ggtttgtgag
cttgaagcca
ggactgagcc
aatcagaaga
ttggtcacag
ttaagataga
taccaccaga
caaggtgcag
ccttgagccc
aatatatata
gggaggctga
gtytccagcc
aaagattagc
agcagaattg
ccccaggctg
aaagaaatat
atagaattcc
acatatgctt
acattgaaga
ggcaagacaa
aaatatttgg
taaaagtaca
gtctcccgag
cccacagtgt
tgttctttga
gctcaagcaa
ctttccaata
tgcgagaaat
agcartaaat
gggcagccac
aaacactggg
aattacaaga
tttagagaac
acccccmaaa
aaaaaaatta
gactgggtgt
aattaatagg
gtgttcacct
agaagcattt
gcggaaaagc
cttaatgatg
gaaatacaca
tctcaaacag
ttaaaaaatc
tggatccttg
ttagatattt
gacaatgttc
tttctgttat
aattctctac
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gcctcagcct
aaactgcttt
cgtcaagcca
aaaaaaaaga
acaaaaacat
aagattctag
gccaggctca
cacatgaggc
aaaacacaaa
ctgaggtggg
acttctaacc
accgtgtttt
aagctctgga
aaagaggaag
gatgaagagc
ttccaggaga
ctgtgtactg
acaataatgc
ctcctaatac
cgcagtatcc
ttgctctagc
gtggaggcct
cccaacatat
tacccaactg
aaatcttgtg
attcagttta
cgcactgaaa
tgactcacac
aggcgttctt
tacaaaaatt
aatgggagga
tgggtgacag
tgggcatgat
cttgaacctg
ggagacagag
ttttaaaaag
aatgacctta
gtgagacaaa
gtactcggat
gtgggtgaac
tatacaatag
cattatttga
tcacagtgca
gtaaataatg
tccctacggc
tgtttatgyt
ggatgtgttc
tataaagtga
catcgggacc
gcccatctcc
ttatttctgt
aactacagga
gtaccatgaa
tagtacatat
tttttaatta
gtgtctgagc
aactgcttat
accawacaak
agatactttc
ggttgagatg
aattctttgg
gaaattcctt
taagaaacaa
agtttggagc
tatgtggttc
gaaatggtgg
atagtccaca
cgtgaatcat
aaagagaatt

cctgagtagc
tgtagagatg
tcctcccact
gagaagaagt
gaagatatag
agacaaataa
gtggcccacg
caggagttca
aattagctgg
cgtgattctt
aagaatttga
atacatgcaa
ggttaggctt
acatgaaata
gatcccagaa
gaattctcca
ataggaaatt
ctacgtgatg
ctcaacaggt
tttataataa
aaattaagca
ggacttgcaa
agaatctgac
gtgtccaata
tgttgatgat
tttaatgatc
gtaatttttt
ttgtaatccc
tgttgtctgg
aaccaggtgt
tcgcttgagc
agcaagacct
ggtgcacacc
ggaggcagag
tgagactcca
tcatactgct
aatgacaaca
ggtgtctctg
actgaggtac
ggcaagactg
agaaatgttc
ctaactttta
tctgtggcat
gtgtggctta
acctatgtat
tacaattctt
agatgttaaa
gttaggatgt
agtgctgagt
ccaggagatg
catgtggatg
gttacacttc
attaatgttt
ttagagaatt
ctaatcagga
aagttacctg
taaggttgtt
tgtcctaaaa
cttaaaggca
aaatggtatg
gtgatttaac
atttttctat
cagaaacagg
caatgggggg
agtttttgta
tggacagaga
gttcagctca
tgttataaaa
cactttaaca

taagattaca
gagtctcact
ttggtcgccc
taaaaaaatg
aaaaatagaa
taggggtccc
cctggaatcc
agaccagcct
acctggtagt
cactaaacct
tacccagcag
aatggaaaaa
caccaatata
aagctggaga
agctagctgt
agatgatatt
gggacaattg
aagcctacat
gaaggtcctg
atgtgcaaag
aacccaaagt
ctggtgtcta
actatctcca
tttggtgtgc
tggggtgtka
tcttgtaatg
gttatcactt
agtgctttgc
acaacaaaat
ggtggtgtgt
ccaggaggtt
tgtctctgaa
tgcagtccca
gttgcagtga
tctcaaaaat
aagaataata
ttgcaaatat
aaactatgga
agaaaaacca
cttttcatca
tatcaaaaag
ggatgcacat
gatgtagttt
caaatgatga
tggccctgaa
catactgaaa
gaattatctc
tagtgcaatg
aaagtggatg
acatcatcat
gccttagaag
tcaggtttac
agaataatcc
aatawagaat
aagccctggg
tttcttcata
gggaatatta
cctttttttt
agagtggact
agcagataaa
aggatgtgag
tagtgatggg
tatgaagtct
agaaaaaaca
ggtggtttag
aattcaaaat
accttcccct
ccagtgatta
agccactttt

ggcatgcacc
atgttgccca
aaagcactgg
agaattaagg
aaaaatgaga
agaaggagaa
cagcactttg
ggccaacatg
gcatgcctgt
ttagggtgcc
agctatgcat
cattcttttt
agcgtggtca
ttcagacaag
ctaccaagat
gatagtatag
gcagaattta
aaaaacccaa
tagctaacac
ataactaagt
ggagggtgtg
agtgaggagg
ggtaggtaat
tgggggaaga
gagcagagga
tgtattaagg
cttattggat
gaggccaaga
gagaaccatc
acctgaagtc
kaagcttgca
aaaaaaaaaa
gctacttggg
gccaagatca
aaaaccaraa
ggttttcatt
tttccacgta
tggtacaaga
agtactaact
ggaacaagga
tgactttgag
ttaattcttc
aattggcaga
catcttagat
tatttatacc
atcagyggtg
tatggtggga
taagtagtag
ntagagacat
catcatcatc
agccacatct
ttctgaggct
atggctccag
tttctaaaca
tgtaagtcag
tgtaagctgg
agtgagataa
tttcctcttc
gagggtattt
cattaacaga
ttttaaaact
tatataattg
ttctggattg
gccttccctt
gaatttagct
gaattacagc
cccaccaggg
agaaagtatt
actatgagtt

http:/ /www.ncbi.nim.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

accatgcctg
agctagtctc
gtgattgata
taaatctttc
aatttaccat
ataaaaaaag
ggaagccgag
gtcaaatctc
aatcccagct
caacccccta
caaggatgag
cttccttgtg
ctaaaaaata
aaggaaatct
tagagaataa
ctgatgactg
gagttgaatt
gaggatgggg
atctcttcaa
atttctctga
ggaaccccaa
gaaatcttag
gtcagaatta
acccccacat
aacactaata
ggtattattc
gttgaaatgg
cagaaggatc
tctattaaaa
ccagctactt
gtaagccagg
acaaggaaag
aggctgaggc
cactactgta
ataaaaaaag
tagttcatca
ggcacggaag
acttcacttg
ctggaagaat
catcagtaag
atagaaataa
acatttttgt
gtcttttctt
ttataaaata
tacaacaggt
tctgactttg
gaaaagaagt
tcttcatagc
tccttgttct
atcataccag
ccacagaggg
tgagtacacg
aggctccatc
tccccaagaa
atttaccact
agattataat
tgaatgaaaa
aggctattaa
tttcctcttt
attatcttgc
ccattttcag
gaaataatat
agttttgaaa
ttacatttcc
aagttaattt
tttttggcag
aacacaggag
tcttgtgagt
accctaaagt

/, October 7, 2003

8701
8761
8821
8881
8941
9001
9061
9121
9181
9241
9301
9361
9421
9481
9541
9601
9661
9721
9781
9841
9901
9961
10021
10081
10141
10201
10261
10321
10381
10441
10501
10561
10621
10681
10741
10801
10861
10921
10981
11041
11101
11161
11221

11281
11341
11401
11461
11521
11581
11641
11701
11761
11821
11881
11941
12001

12061
12121
12181
12241
12301
12361
12421
12481
12541
12601
12661
12721
12781

cacctcgaca
tacctgccaa
aggaaagaaa
ctgtaatccc
gaccagtctg
aaatgtaaaa
cgcagagtat
cagccagcaa
gattcaagtg
caattcattg
tataaacaga
tgaggcaaca
gggtctaaag
ggctcacacc
gccaacatgg
tacgcttgta
gcggaggttg
aaaaaatata
tgaactgagc
tcatttatgt
actgaccatg
ggtttttggt
tcatagctca
ggataacagg
ggctatgctt
ataatgtttt
gtatgtttac
tacaactaaa
ggtacagtca
gggaaaaatt
aagccttagg
gaatgcacca
ccatattgta
ggttcctgtt
tttccccacc
aggcacatgt
tgtgcctaga
aattctgttc
aggcagatca
ctctactaaa
tctggaggct
gattgtgcca
ttttttttga
ggtggctcac
tcgggagctc
aaattagcca
gagaatcgct
ccatccagcc
aattaccagg
ttttaagcaa
ttcactttag
tgtaaaattc
agcgacagat
agaaattgaa
atatctataa
atttttattg
aataatatag
aattcctcta
tgaaaacata
gtgtagttgg
tttcttactc
ttgatttggg
atgaggatac
ctatatagta
gacatatgta
ttatttttat
ttgaagagat
gtttaggaga
gacacagggt
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tcattctcta
gatatgcatt
aaagaatgta
agcactttgg
gacaacatag
tataataacc
gcatgcattt
ccaatcaact
tggtcatgaa
agccagaaga
ttgtcatgtg
ttaggaaaat
ccatttgtaa
tttaattagg
tgaaaaccca
atcccaacta
caatgagccc
tatatatgta
tactgtaatt
aactgatcta
agctaaggcc
tttttgagac
ctgcaacctt
cataagccac
catttttcca
tgtttacatt
agatatccta
cagttcatgc
gtcctgctat
tgagcatgaa
taaaagcaga
acatccccca
gtatttatct
tttgtttttt
agcctgggga
tacattatag
tatttgtacc
attataaaac
tttgaggtca
aatacaaaaa
gaggcaggag
ctgtactcca
ggaaaaaatt
gcctgtaatc
gagaccagcc
ggcatggtga
tgaacccagg
tgggcaacaa
acaatgctat
atggaaacta
tacagtagct
agttcctcaa
atagacattt
aagcatttcc
ttacattcca
tttcctgaat
atctgctttc
aattaaagaa
atttaagtgt
tgtggaaatc
agaagaacca
taaataattg
cattcatgtg
taagaagcaa
tataaaagct
taacacgcat
aaagataaca
gaagagaaac
attaagggaa

tactgaactc
tatttataag
tgaaaaggtt
gaggccaaga
accctgcctc
taaaaaatgg
tttgggagtt
gtagctgaga
attgagaata
gatagttact
atgtcaccat
ggtatgaaat
taaagacatt
tgagcggatc
tctctactaa
cctgagaagc
atgcactcca
tatatacgta
acatgtaaga
tgtattgagg
aaaaagcatt
agtcccactc
gaactcctgg
cacacttggt
tctgttgaat
ttataactta
agaaatacga
tctgcccaca
acttgtttca
ataaatttca
aaactgcacc
gctaccttag
atttctcaac
aatgtggcac
tttttagtgc
cagaactatg
actggtactg
ttaccaggac
ggagttcgag
ttagccgggt
aattgg\:tga
gcctggctga
ttcctctttt
ccagcacttt
tggccaacat
caggcacctg
aggtggagat
agtgagactc
ttgtatatga
caagattagt
actagccaca
tcacgaggaa
tcatcaatgc
tctagtcaaa
actgtttcat
tcatataagt
ctgcatgttc
aatatatgct
aaatgtatga
agtgaacttg
atcaccgaaa
tatccatatc
tccgatggtt
gggcttaaaa
gaggtcaaag
tttctgagaa
cagcacaccc
agggacaaag
gagatgggag

tcttgtaatg
cttgaatgtt
agtaaatgcg
cagaaggatc
aaaaaataaa
tctattctga
gattttcaag
gcctttgtta
tttaaactat
ttcaaaatta
aaatggtaac
agccaattaa
ccaaaaaata
acttgaggtc
aaatacaaaa
tgaagcagga
gcctaggtga
aatacagtta
agttaagaag
tctatacaga
aaaacaaaat
tgtcacccag
gctcaagaga
cttattttgt
gggaaataaa
aaaaatgtag
aagatgaaag
ttgaaagtac
aaactgaatt
catttgcttg
cagttgaact
tgagcattag
catttaacat
tgaccaagtt
gtgatttagc
tttttatttc
ttttctcttg
tgtaatccca
accagcctgg
atggtggggc
actcgggagg
cagagtgaga
cctcaaaatt
gggaggctga
ggtgaaaccc
taatcccagc
tgcagtgagc
cgtctcaaaa
taaaatatac
atacaaatga
tgtggctatt
ccaatgtggc
agaaaatttt
tcaatttgta
acataaaaaa
cagtttttca
tttgaaaccc
tactctaata
ttttatgcag
ggatacaaga
ttcctggaac
cccacaaaag
cctatttagc
atataggtga
cctctctgta
cccatcatgt
ccctcactcc
ctatttgtaa
ttacctgccc
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ataatataca
gagaactttg
ccaggtgtgg
tcttgagccc
tttaaaataa
atataaatat
tagagatgat
gagggctgct
attatgacat
ccctcaaaaa
aatgtagtac
atgtgattgt
tcagactggc
aggagttcga
attagccagg
gaattgcttg
cagagtgaga
tttttatgta
ttatgatagt
catgagatgt
gtttaagata
ggtggagtgc
tcctccctcc
ttttattaca
aacacataca
ggagaatttt
acaagttata
gtactctttt
ctaactcaat
tgtgtgattt
aaaccaggta
gtctttttca
gtataaaact
tttaaatgct
atagtgcagt
acttgacata
agtccaagat
gcactttggg
ccaacacggt
acacctgtaa
tggaggttgc
ttctgtctca
accaggaaaa
ggcaggtgga
cgtctctact
tactcaggaa
cgagattgtg
ataaataaat
aaatttttgg
gtgctaatgt
taaatgtaaa
taatgcctat
aatgggcagt
ttaaatcagt
agatatatat
gaatttttat
tatgaacctg
taaccctcta
gtttgcagac
attttttaca
caaagtwttt
tttttctcag
acgcagattc
tagctaccta
ctcaagcttt
gccagaccct
cacccctaaa
tgcatggagc
aacctggcgg

http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

gatacaatca
accactgagc
tggcctccgc
aggaatttga
aagtattaat
cggtgactaa
agaatttttg
atgactttaa
atattttaac
aaattaactc
aaacaggttc
tgaatatttg
caggtgcggt
gaccagcctg
catggcagcg
aatccaggag
ctctgtctcc
tatatatata
agatgatttt
gaatagaaaa
tttaggttta
agtggcatga
caacatgctg
ggttgtagta
gccaatttga
taaactccct
tgtttcattt
gtagataaaa
tgatatatta
catctataag
tgaatagatg
ccgtaaagtg
gttattatta
gtgccctcac
gattttagga
aaatcataac
cctgagactg
aggctgaggc
gaaaccccgt
tcccagctac
agtgagctga
aaaaaaaaaa
gcccgggtgt
tcacctgagt
aaaaatacaa
gctgagacag
ccattgcact
aaataaataa
atagtgttta
tctagacctg
ctaaataaaa
tttattggac
gctgatttag
attttgttat
aattttccaa
aaggtttgaa
aattcatata
tttagtcatt
cggggacaca
gagcagaatc
aaggtttgtt
cgtgagtatt
actgtagata
aataggtata
taggcttgtt
gcctaagaca
gaatctctta
taagtgtaaa
tgcttcctga
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12841
12901
12961
13021
13081
13141
13201
13261
13321
13381
13441
13501
13561
13621
13681
13741
13801
13861
13921
13981
14041
14101
14161
14221
14281
14341
14401
14461
14521
14581
14641
14701
14761
14821
14881
14941
15001
15061
15121
15181
15241
15301
15361
15421
15481
15541
15601
15661
15721
15781
15841
15901
15961
16021
16081
16141
16201
16261
16321
16381
16441
16501
16561
16621
16681
16741
16801
16861
16921

agcatggtga
cgggaagata
gcctcctggc
tgagcaagga
atagacccgc
ggctcagata
ttttctagag
atggagtgag
aatgagccag
agagactcaa
ccggcatgtg
ggggcatcct
tggaagaagt
aggttgtgaa
gaaaatttag
aaaaagagaa
gaggaaaaaa
tgtctgattt
ctgggaaggc
gcaccatgtt
ccattttgaa
gctgctcttt
tccgtatcct
cagagttgta
actcttttct
cccagcactt
atggccaaca
gtgcatacct
gaggtggagg
aagactctgt
ggtatttttt
agtttactca
cccgcccagg
gtcttacccc
tttaaagctc
tccaggccca
cctcctctac
tgtgctgaca
tgttatattg
aaaagtcacc
ggattatttt
gggcagtggc
catgtcagcc
ttctgtagag
cgatctgcct
gccaaaagtc
ttctgtgttc
aatgttctct
gtcgaattca
caaataaatg
atttctggaa
acctgcagat
aattttatag
gatattcctc
tgccaataaa
ctagaacttt
aaaaaaaaat
tgttgcagta
ttgaatgctt
cctgtgtaac
cactcgtctg
gaggcagcta
tgtaatagaa
tgatacctga
atgtccccaa
ggatggacag
gatcctaata
cttcttaaag
attggcaaat
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cagatagagc
ctacttaaat
agagagacag
gagtgatggg
aggattctgt
gactggctgg
atgatgagtt
gtttgggctc
tgtaaataaa
aggcaggcag
ctgttgcgag
atgtgattgg
gtggtagtaa
gtggctacct
gacagagaca
agagaaaagt
cctgccaggt
acatagggct
tggtcgcccc
gtctgcttct
catgattggc
gttagaaagg
ccctatctgc
ttgtcatata
aaatattgaa
tgggtggcca
tggcgaaacc
ataatcctag
ttgcagcgag
ctcaaaaaaa
atttcacatc
gtccaaaaag
ctgcacattt
aggccaatta
cccttgattc
cccatctctg
ttgtaaacct
cacctttcct
ccccctcttg
tctttttttg
gctccaagtg
acaatcacag
tcccaggtag
ttggagtttt
gcttcagcct
accttttgtt
acatagttcg
gtgcccacgc
aatctactgt
ctcattggct
taacttaaaa
ttatctttag
caagctctga
tgagttggcc
gtgcagtaaa
tgctttgctt
tttttttcat
tttttgatct
gccaggcagt
atccacaaag
cacactttaa
gggaaaaaga
atgaatttca
gccagaggct
atcataacag
ctctccacac
ccttgacgat
atttgatttt
ttgacatgat

tggaatcagg
cacccatgag
gaggctatgg
gcatagagag
gaccgaatga
atggtcaaga
taagggacct
aaaatgatag
caaacactac
aggagtgggg
gctgttggca
tttggggagc
aaatcaggga
tgtctggggt
cacatgagga
aaaacagctc
gtagaagcgc
cacagattgg
accctaatct
tactctacag
acaaactgcc
aaaaatgatt
cttagtaatt
ggatctattg
attaattgct
aggtgggtgg
ccatctctac
ctactctgga
ccaagatcgc
aaaaaaaaaa
ttcctcccac
ggctagtcct
gaaatcatct
tatcagaatc
caatctgcag
ggctgaccca
gtgtggggac
acmctgccct
gagtgtgccc
ttttattctc
tttgtttttg
ctcactgcag
ctggaactac
gccatgrtgt
cccaaagtgc
tagtctccct
caggcacaga
ttctctgctc
caagaaccca
gaatgaatga
tacctgactt
cagagtaaaa
agtgagtaac
caaaagaacc
attatttact
ggccctcttt
tatttcatta
tcccaggtag
gcaggcatgg
catttttttg
tgtgttttgt
aaggtgagta
agtagccaag
gggggcagag
agtggggagg
ccaggtccac
tgttgaagta
tctcccataa
ttgggataga

cagggcctgg
gcctcatagg
cagtggtcca
tggttaggat
ggaccaaagg
ataaatgaga
gtggagtggt
gtttgggagt
ccaagtggga
aagcttaaaa
cagggaagct
atgtttgcct
agctggcagt
aaattcccca
gttcaggagt
tctctttagt
cggattttat
ttcgatcaag
tattatgcaa
gtggctgaca
ggcatctatg
tgaggctgct
tcttcttaac
tccatctgta
cagctgggca
atcacttgag
taaaaatgca
ggctgaggca
accactgcac
attgttgctc
ctcattctca
gcttccaggc
ctggatctta
tgtaggggta
gcaaagttga
gtgatcccag
ctcatttcag
tcaccccagc
ccagtccaca
ttgatttttg
agacagggtc
ccttgacctc
aggtgtgtgc
ccaggctggt
tggaattaca
gatgctcccc
accacaacag
tagtctgtcc
ggatagatgt
gcaaaaatgg
ttcagtacca
atgtcactct
agccaactga
tcgcacaggt
ttaattatgt
ccttgactat
cagagttctt
gttgaatact
gagtggaggt
aatgtctgtt
ctttggttag
agacagtgtc
ggagataaga
ttgttgcaca
ctgctgccac
acattcctct
ccagcatgca
aatgtttttt
ggagcattag

gtccatggtc
aagtgatttg
ggaaagacat
ggattaaagc
agcgatgagt
agggcagaaa
gaaggtttta
ggtctttatg
acaagcagag
gtggacaaaa
ggaggtgggc
ttctctggct
cattgaccaa
ggttcgtcgt
ggaggtttaa
gagagagagg
agtgcagcct
tgtgatgttt
atgaactctt
gagaagggaa
tctgcagctc
tttcattaag
tcctgaatca
tattcagtgt
tggtggctca
gtcaggagtt
aaaattagct
ggagaatcgc
tccagcctgg
agatcagtag
aagcattaaa
ccctcttgga
taaaaattcc
gggccctggc
gatccagctg
gctggttgtc
aataaaatct
tcccaggatc
ccctagagtg
ttgttgttgt
ttactctcac
ccaggctcaa
caccacaccc
ctcatactcc
ggtgtaagct
aggcaggccc
agcaggccat
tcactgtggt
cttgtctatt
aagaatcagc
ccctgcctga
gctcgaggaa
tcttcaaggt
tttaaaagaa
ttaattaaca
tcaagtactt
cggggaacat
acatctgcac
gtcttcctca
ctgcagatat
ctcccaaact
ttctaccttg
gctcatctcc
ctgtcctttg
aggctcctaa
aggaggaaac
ccatggggga
ctctttctgg
ttgccattaa

http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

ttggacacct
aagggaagta
catgaatccc
aacatttacg
tcacatttct
gaatgaatct
tgtctgaagc
ctgtgagcag
agaatctggc
gtaaaagctc
aactaggaac
gatcctaaat
gtcactgcag
cttgtgccag
taggcaaaaa
ggacttccga
gaggagtcag
acataacgtg
cccttcactg
gatagagcca
gattttatag
aggaaaacct
gttgtggggt
ctcacaaagt
tgcctgtaat
caggaccagc
ggctgtggtg
ttgaacctgg
gcaagagagt
gaagcttgat
gaatccaagg
gcagcagttc
caatccaaag
atcagtactg
ttctcctgcc
aaagaccctt
agcagtcttg
ctaaagtcta
tcaccctttc
ttatttttta
acaggctgga
gtgaccctcg
atctaatttt
tgggctcaag
gccacacctg
ctgctctgcc
tctggattgt
cagagactgt
aggtactcag
acaattgcac
taattggttg
acattgttag
tgtcctctgt
aaaaataagg
cattctttcc
actaagtaaa
ttcattgtac
tttaaaaaat
ctctcttcct
ttttattaca
atgggaaact
cacctgggcc
tgaaagtccc
ttccttcttc
aaccatgagg
gcagacgtga
cgctgctcat
taggacaaat
tccaggtgat
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16981
17041
17101
17161
17221
17281
17341
17401
17461
17521
17581
17641
17701
17761
17821
17881
17941
18001
18061
18121
18181
18241
18301
18361
18421
18481
18541
18601
18661
18721
18781
18841
18901
18961
19021
19081
19141
19201
19261
19321
19381
19441
19501
19561
19621
19681
19741
19801
19861
19921
19981
20041
20101
20161
20221

20281
20341
20401
20461
20521
20581
20641
20701
20761
20821
20881
20941
21001

21061

cgcaaatggt
actttttctg
gtttggaatt
actacagaga
ggccttggtc
tttctgtaat
ggncactngc
catacatgta
tttgagacca
tccgaccgtg
gagcccagaa
gacagagcaa
tttcatgtgg
aggaaactga
agagttgaga
gtggctcacg
caggagttcg
aatcagccca
acttgaaccc
ggacgacaag
atccctttgt
ggaaatacct
gttattgatg
aaatatgagt
aaaataatgt
gtatggagca
aatcccagca
cctggccaac
gcgcacacct
caggtggagg
gagatttcat
cagtgaaata
tatacttttt
tctcactgct
tcgtgattcc
atttgtccta
agacggagtt
caacctctgc
tataggcatg
ctccatgttg
acccggtgct
agatcaattc
ttccaaatag
cgctctgaca
tccagtgtct
accgagacct
aatttgtagg
ctacaggctc
ccacgtgcag
ctggaggtca
ttaataaatg
atattagttt
cttgttgccc
gggttcaagt
acacccagct
tctcgaactc
agatgtaagt
atcttagttc
gtgctttcgt
ttttctgctg
tctggacttt
ttcagtccta
tcttctgaaa
gttctttcac
tattagtctt
gtcaagctta
gtctgcactt
ctccgtagaa
catctttgtc
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aagtaatttt
ggttctagaa
tataaaaacc
cctgggtgta
caagtattca
actaacacaa
ctatgccagg
atcccagcac
gtctgggcaa
gtggtatgtg
gttcaaagct
gaccttgtct
tttaacattt
ggtcaaagag
ttcaaaacca
cctgtaatcc
agaccagcct
atgtggtggc
aggaggcaga
agcgaccctc
tagactacct
tgtcatctct
tttttgatga
gaggaagcat
catttatgtg
gactcatcac
ctttaggagg
acagtgaaac
gtagccccag
ttgcagtgag
ctaaaaaaac
agatttttat
aaattagacc
cctcctttat
ccaagggacc
ccagaaagaa
tcgctcttgt
ctgccaggtt
ctccaccaca
gtcaggctgg
gggattagag
tgttactttc
atagtatgcc
gtctttacat
gctttgcact
ctgtctccgt
tgtttcccac
tggttggcat
accaagagcr
gttatttccc
ttgtttaaat
actatgtact
aggctggagt
gattctcctg
aattttgtat
ccgacctcag
caccgtgccc
tttatctaca
taggactggg
tgactctcga
ttgagactgg
ggaaacccta
aatgagaatc
ctacaaggaa
atcctcatgt
catagccagt
gcctccccaa
actggagtgc
cttggcctgt

tctttttttg
aatcagctta
taaatccaat
aggctataag
acttctctaa
tcatcaccac
tattgttcaa
tgtgggaggc
caaagcaaga
cttgtagtcc
gcagtgagct
gtaaaatatt
aattctgtaa
attaagttac
gagtgtttgg
tagcactttg
ggccaacatg
ctgtaatccc
ggttgcagtg
catttcaaaa
caaaggattt
aaagaactgt
ccattcttat
actgagtaaa
cttacttgga
ttggccaaaa
ctgaagtggg
cctatctcta
ctacttggga
ccgagattgt
aaacaaacaa
ttttaaaaat
atgccgcatc
ctcttttcca
accatcctca
aaaaaaattt
tgcccaggct
caagcgaatc
cccggctaat
tctcgaactc
gtgtaagcca
attcagctat
agaggcgggg
ttccagctct
tcccatgtga
gagacacatt
tccctgaaga
ggtaaaatcc
gcaccsagca
cagtgtctga
aaatgaatgg
ggtagtatct
gcaatggcat
cctcagcctc
ttttactaga
gtgatctgcc
agccttatct
tgctggtact
tgtcttctcc
gttcttgcct
ttgagagaga
ccaaaccagt
agaaagtaac
gagtgatcca
tacaggtgag
cagtagagga
cttctggcag
caagagccca
ctctcatggc

tttagctgtc
gacttctatg
actagctttg
gcttgtggct
gctttggttt
ctccactaat
aatactttat
caaagcagga
cgccacctct
cagctacttg
atgatcgtac
taaaaaaaaa
ggtataagct
ttgtccaaag
ctttgaagtc
ggaggccaag
gtgaaacccc
agctactcag
agccaagatg
aaatgaaata
ttgtgggaat
ataaatgaga
tataccgagt
atgtgaccac
tatagcatgg
aggaggctgg
tggatcatga
taaaaataca
ggctgaggca
gccacggcac
ccaaaaaaaa
tgtttcatca
ttaattttca
gaactcccat
gccttatgct
tatgagagaa
ggagtgcaat
tcctgcctca
ttttttgtat
cggaccccag
ccacgcctgg
tcaacaaata
caagtaactg
gttctttctc
catcagtgtc
tgtatatgaa
tgatcatcca
accaagcagt
ctttggggag
tataatatat
aagaagtgaa
tagggttttt
gatctcggct
cngagtagct
gacggggttt
cacctcggcc
tagtatttta
cagtacttac
ttagattgta
aatgtaaacc
aaacttcaca
ctgacatccc
agtttctgtt
ctggtgaatt
gaaactgagg
gctggggttt
acctctggac
ggctccttcc
ctctctacca
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ttaatttttt
agtttgaaat
tctaaaaagt
caatcacttt
actcctgcaa
attaccaggt
gtgggctggg
ggattacttg
acaaaatatt
ggaggctgag
cactgcactc
aaaaacaaaa
actattccat
ttaagcagct
catacttgtg
gtgggcggat
atctctacta
gaggctgtgg
gcgccattgc
aaataaagtc
tgaaagaaat
gctgttatta
cttgttagaa
atctgtatac
aaatactgaa
gcgcagtggc
ggtcaggagt
aaaattagct
ggagaattgc
tccagcctgg
aaacaggtta
gtaaggctta
tgctcctgtt
cctccttgca
ctcacccaaa
aaatcaaatc
ggcactatct
gcctcccagg
ttttagtaga
ctgatccacc
ctgaaaaatc
tttactaagt
aacagattat
ccaaacatcc
ctttaacaac
accccatctg
ttccttagag
gggaagcaaa
gctggaggtg
atttagcacc
ctgcactctg
ttttgagatg
cactgcaacc
gggattacag
ctccatgttg
tcccaaagtg
tatatgtgct
catgttagca
cgttgtcaag
agtagggcag
ttctaagagg
cctcatgggg
caaaagtttg
ctcacagttt
tacagaaagg
gagcctgggc
atagatacar
tcagtgtggg
ccctgcatgc

http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

agtatactat
aggttattat
ataggatttg
caagctgtgt
aatgggaata
aatacttact
tatggtggat
agcccaggag
tttaaaatta
gcaggagggt
caacctgaat
aaatcaaatw
tatacagatg
ggtatgtgac
gccgggtgtg
cgcctgaggt
aaaatacaaa
caggagaatc
actccagcct
cacactcatg
gaaatatgta
ttgaagcatt
aataaaattw
tctttcaatt
ttacttagtt
tcacgcctgt
tcgagaccag
gggcttggtg
ttgaacccgg
gcaacggagt
ggctccccat
ctgccaaacc
tccctctttt
tgcctaaaag
aattgccaat
ttttttttcg
cggctcaccg
tagctgggat
gacggggttt
cgcctcggcc
aaatctttaa
tcctgtgatg
acatggtatt
acatcacatg
tcaaaatatc
ctaatgtcta
gttagtcctt
ctaaaagtca
ggcagatcac
tagtaagagc
agcaagggcg
gagttccact
cctgccttct
tagcgccacc
gtcaggctgg
ctgggattac
ggtacttagt
cattatattg
tactgatgta
acctcatttt
aatgaagtct
acagcaagtt
ctttgatgtg
gtgaggtggt
ttaagaattt
atctcataga
tctagccagg
gaagggtgtc
gtctcctgtc
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21121 ctctccttat
gtcagcctcc
agctaattag
gtcaactcat
tgttagcatc
aaggacagtt
accttttttt
ttttctctta
agcatcccag
cttttctttc
cctcaagcac
agtctctacc
atttgattcc
tttctcactt
agtatcagcg
22021 tgtgtagaga
22081 tttccctcct
22141 aacatccagg
22201 gatataaatt
22261 tactgcatat
22321 ttctcttcta
22381 caattcagac
22441 gagtcctatt
22501 tggtagtgat
22561 tggggatgca
22621 gttttataat
22681 ctcctggact
22741 aatacataga
22801 atgcttgttt
22861 tttsagacac
22921 ctgcaacgtc
22981 gattacagtg
23041 caccatgttg
23101 tcccaaagtg
23161 ttgaataaat
23221 tcagagacaa
23281 atttaaattc
23341 aggccctgtc
23401 ttccttatac
23461 aggagttggt
23521 tggaatccac
23581 agctaaagat
23641 tctttagtat
23701 ggataatgaa
23761 tatttctctt
23821 ttggtaagtt
23881 gcctggcgtg
23941 cacctgaggc
24001 aaaatacaaa
24061 ctgaggcatg
24121 cmctgcactc
24181 gaactattag
24241 ttattgaaag
24301 atgctatatg
24361 ttatttgttt
24421 caatcacagc
24481 tcccaagttt
24541 tgtagagatg
24601 tcctcttgtc
24661 gtgtatttan
24721 tttgccctta
24781 gtttttaaaa
24841 gcctaggcta
24901 aagcgattct
24961 ccagctcatt
25021 gaactcctga
25081 gtgagccacc
25141 catagtattt
25201 ttgagaaggt
21181
21241
21301
21361
21421
21481
21541
21601
21661
21721
21781
21841
21901
21961

NCBI Sequence Viewer

ccctcagctt
ttgctccaac
caattcctct
cgtctgtacc
agcttcccac
ccattgcact
tggcctgctt
cataaggccc
gccccatggc
aacaagcacc
acaggcatcc
catccttatg
catctggacc
ttaaaatgag
aaagtaactt
aatgtaacaa
gggaaagaag
taaagttgtt
ctatgacatg
atacatggag
tattgtacat
tagagaagag
gggaagaagg
gtgttggaca
gaagttgtgc
ctatctattg
cattttaatg
cttttaattt
tgtaaatatt
agtctcactc
tgccttccgg
tatgccatca
gccaagctgg
ctgggattac
tggggtctta
tcaaatggaa
cattaatgaa
tggaggtgga
tctatatcct
agaaaatcag
tctgatttca
ggatatgatg
gagatttgca
gttgtatgta
ttacctaggt
tgtggactta
ctggctcatg
caggagttcg
aattaggcca
ggaattgctt
cagcgtgggt
tatattagta
ttgttttatc
ctctatgtta
atttttgaga
tcactgcagc
ctgggaccag
gggtttaacc
ttggcctccc
ttttactctt
gcattcctct
taatttcaag
gagcgcgatg
cctgcctcaa
ttgtattttt
cctcaagtga
gcacccagcc
taacatgtta
tgatgctttt

cctccatttt
caccatacaa
ttggtctctt
tggtccagcc
tctgagccaa
catggtttat
gttactctca
ctggaggggt
aaactaactg
ccagtgattt
aaggtcagca
taatgtcttc
aattcccagc
aatcaacctc
ctggcttcct
ataccttctt
tttcagtatc
ggtttttttt
gataagaatt
ataattccag
gattttactt
cggggaaatg
aggaatgtgg
gatgccttca
aggaaaaact
cattctttta
cattcaaaca
gtaagagtca
tacatatgtt
tgtggcccag
gttcaagtga
cacccagcta
tctggaactc
aggcgtgagc
aaaactcatt
atagaaatta
cagaagccct
gtctaaggat
gcagcagagc
tatgctagaa
atgagcctaa
gggatgtaac
aaagaagaat
gaacaagtac
ccaccatttt
tgctgtaact
cctgtatttc
agaccaccct
gtgtggtggc
gaacctggga
aacagagtga
tctagagtat
ttagaaaagg
aaggtatttg
taggatcttg
ctcgacctcc
aggcatgcac
acattgccca
aaagtactgg
gggagttaaa
gttttgatta
gttttgtttg
gtgcaatctc
cctcccaagt
agtagagaca
tccacctgcc
aattttgagt
ctctttcttg
gaagaacgac

tattcccaca
tacaaaagct
aattcagttt
ctggcttctg
tcagacctgg
gccacacttg
tttctaacta
cccagtcacc
catcggtctg
tgacacccag
ggccctcgag
tgctctgatc
ttaggcaggg
ttgtgattat
tccctgcctt
gtgttctttg
tcctgtgtgt
ttttttcttt
attttctcct
ttttgactaa
gtattccttt
gatgatcctg
ttggatattg
catacacaag
ctaaattatt
tttgttttga
ttgaaactta
cctttttgat
agtattttgg
gctggagtgc
ttctccwgcc
atttctgtat
ctgacctcag
caccgttccc
aaaagatgag
atagaggcas
aacaaagaac
actgctctta
gggaggggtg
gatggttgaa
gtcccttgac
attgccatcc
gagaagaaca
acctacgtca
atgttccaca
ttttaaacaa
cagcactttg
ggccaacatg
atgtgcctgt
ggcararagt
gactccatct
gtctataaaa
aactaatctc
aacttttcta
atctgtcacc
ctgggcacaa
cacaatgctt
ggctggtctc
gattagaggc
agtgataata
aaaagaagag
tttgttttga
agctcactgc
agctgggatt
gagtttcacc
tcggcctccc
atttttaaaa
tttcaggtaa
ataaaagttg
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tagctgactt
ccaactttca
ccaagtcagt
ctcagtctat
ctccctgagg
cagagcttta
aatagaggaa
caggatattt
tggggatgga
cctggtctag
tacctcatca
agctctggaa
gccataattt
taggagaatt
ttgtccctcc
tagctatgca
tctttcttat
taccagttgc
aatttatctc
tgggaactat
cccattttgt
atacagaaga
catatccgta
cacggggtga
gtcctttttt
atctgttggg
acctttgtca
tttcaactga
cttttatgtt
agtggtttca
tcagcctcsc
ttttagtaga
gtgatccgcc
agctagtatt
acctagtgtc
aagttagctc
ctttgggaag
gaagggggcg
tataaaatgt
acccccaagg
cggtttagct
tctcagtaag
tgccacatca
ttggaaataa
tgctgaaatt
agtcaagtta
ggaggccaag
gcgaaaccct
agtcccaact
gtagtkagcc
aaaaaaaaaa
tttaaaagat
tgtaaatatg
gagagatggt
caggctggag
gtgatcctcc
agctaatttt
gaactcctgg
atgagccgcc
acaattcaga
aaaaatgttt
gatggagttt
aacctccatc
acaggcatgt
atcttggcca
aaagtgttgg
gaatccctga
aatatgcaat
gggaattgac

http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?cmd=&txt=&save=&cfm=&

gccttcaacg
gtaggaccac
catctgattg
tgatgggtcc
cacctactca
atttcatgcc
aaaaattgtg
gttaaattgc
gctcaggcat
aaaccactgt
ggccagaagg
gcaggcctcg
gctaaaccca
taaactcagt
agcctttgcc
gatacaatgt
gatccaacta
ctagtttctt
ataggaagca
aagcatgttt
ttaccattca
gaaatctcat
tcacccaaag
gaagtgaata
aatttctgaa
ggtatgtttt
tggctggaga
gctttttaac
ctgttttgtt
tctcggctca
aagtagctgg
gacaggattt
ctcctcagcc
ttgtttctgc
cctaattaaa
tgctaatctg
aaaatacagc
gaagctcagc
gggtgagtgc
aatctgctga
gtctcatcta
tcaatttatt
tcacctattt
actcagaatt
gaaaggttgt
actcttttgg
gtgggcagat
gtctctacaa
atttgagagg
aarattgtgc
aacctattgt
aaagaccatt
ctctgtatat
atatattttt
tacagaagtg
cacctcagcc
tctatttttt
gctcaagtga
atgcccagtg
gttcaggaaa
agtgtacact
cgctcttgtt
tcccgggttc
gccaccatac
ggctggtcat
gattacaggt
tgtcattctt
atacgttgtc
tgtctttttg
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25261
25321
25381
25441
25501
25561
25621
25681
25741
25801
25861
25921
25981
26041
26101
26161
26221
26281
26341
26401
26461
26521
26581
26641
26701
26761
26821
26881
26941
27001
27061
27121
27181
27241
27301
27361
27421
27481
27541
27601
27661
27721
27781
27841

aaaagttata
catgtttttg
aaattgttta
tactttttct
ttggagagga
tttaccaatc
ttaaatataa
tttcgttctt
gcctcccagg
tgcgccacca
ggtcaggctg
gctgggatta
tgttgaagaa
ttagttttta
ttctccatgt
caagaaacaa
gaataaattt
ctgtttaaat
tattatgaaa
cctctataac
aggatggttg
gtgctggctt
acggtactct
acaaacttct
ttaatttgaa
cgatactgtg
gacaactaac
tgtagagaca
agcagtcctc
ggccctcttc
tacaaaaaaa
gaggcaggag
ctgcacgcca
aaaaaaagaa
ggcagccaca
agaaccaaag
gcccagggtg
tgcccaaaga
tgtgtcttca
taaattattt
ttttattatt
atgccttgcc
gcagacagga
gaaaaataca

NCBI Sequence Viewer

tctacttaca
aggaattgaa
taaatcatat
aaaaaagttt
gattatgatg
agcatgtgtt
tacacacaga
gttgcccaac
ttcaggtgat
cgcccagcta
atctcgagct
caggcgtgag
ctataacatt
ctataaaccc
atataacaga
atacatttta
ttctttaagt
catcaggtct
ggttagattt
tctgtactac
tgtattataa
aaaggttgtt
ccccagagat
accctagaag
gcaactcctt
ggcttcagaa
ccgagctgga
gggtctcact
ctgtcttggc
ataggctttt
ttagccaggc
aatcacttga
gcctgggcaa
aggcaagttg
ttccagcaca
agaggccacc
gggagaaaca
atcttaaata
ctggggaata
tagagcaatt
taagtaacag
ctgcctatga
caaagtaaga
aagaaatata

gaaaagtaaa
aattatgcta
gatagatctt
tagaagaaaa
tgaaagetta
acctgtacaa
aaaactggca
ctggagtgca
tctcctgcct
attttttgta
cctgacctca
ccactgcacc
tcagtagggt
ttgtctttta
atcaagaaac
attaaacaat
tttctctgag
tataaaatat
ctcagttctt
ccaacaacta
aaaacgagtt
aatgcaaggt
atgtcttgtc
ctctctgcca
gctcacagtg
gccatgactc
ccaacacaat
ttgttggcca
cacccaaagt
ggacttggga
gtggtggcac
acctaggagg
cagagcaaga
actgctgaaa
tggatctgag
tgcgtcctgg
ccctgtgtcc
caaatgagat
ctgacttcct
aaattgtttt
attatctgag
agcaggcatg
aaggtacgta
accaaagctt

tgagacatag
aagcctgaaa
tactaaaaat
agatgtaact
tgcctatgtg
ttaaaaaaat
tttattttgt
atggtgcaat
cagcctcctg
tttttagtag
ggtgatctac
tggcctgaca
tcaaggtggt
ctcagatcct
aaattttaat
ctatatggaa
tttggcaatt
aatgtactta
ctttaaccac
aatggtttag
acgtgtgtgt
ttggggtccc
agcctctcta
tcgatgtatt
attcttgctt
cccaactctg
tctctccaga
cgctgatgtt
gctaggatta
atagaaaagc
gtgcctgtaa
cggaggttgc
ctctgtctca
ggggaatctg
aaacagaacg
gtccattttc
atgggataga
atccttaggt
aaaatctcaa
caggattttc
cctctgtgcc
aatgctccag
ataattaatc
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ataaaataaa
atgtaatgga
ggctttttag
aaacttttaa
tcttgcagat
atttcaaaat
tttatttttt
ctcagctcac
agtagctggg
agacaggatt
ccacctcggc
ttctttatga
cccaaaagtt
agcatccctt
taaacaatct
caaacattcc
gttgtttttt
gagctggatt
attttgttat
attgtttagc
gtgcacgcat
ctttaacact
gttccccttg
ctaatagatt
ctctgagacc
cctgtatcac
gacttttgat
gaacttgacg
caggtatgag
aaccccgtct
tcccagctac
agtgagctga
aaagaaagaa
tgtacgcctg
ctgatctgca
atcctccctg
gtcctttccg
agttgatcat
gatggaagat
caaaaatgct
ctgcacacag
tatagacagt
tatttgggtg
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atcacactga
tgaattttta
taaagccatt
agtagctcct
tgcaagatat
gcaatgcata
tgagatggag
tgcaacctct
attacaggtg
tcaccatgtt
ctcccaaagt
aatttagaat
atataaaaga
ttcacatggt
gtaacagaat
caaattctaa
ataatttaat
catggctgtt
atcagacagt
tcatgttaat
gcacgcacat
ggtgaaagct
gcctgcatgt
tgtaaggcta
tgctcccagt
cggttgaatg
tttactttta
tgaggcctca
ccattgcgct
ctactaaaaa
ttgggaggct
gatcatgcca
aaagaaaaga
ggagctgtgg
gaaagagatg
aagcccagct
cttgcagttg
ttatgtaata
ataccacatg
tcttgtttca
tggtttataa
gttatcacta
aatgtggaaa

Appendix 3

Gene Scan 2500 size standard was included in each sample
for analysis using the ABI Prism™ genetic analyser.

Figure A-6. Electropherogram of GeneScan 2500 run under native conditions
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